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Supplementary Table 1. Studies included in the meta-analysis of GWAS on CCT 
 
Study Datasets N in analysis 
CCT (µm) Age (years) Sex 
(femal
e%) 
Genotyping Platform 
Imput
ation 
Y/N 
Lamb
das 
Mean (sd) Range Mean (sd) Range 
Set 1. Samples with European ancestries and unaffected with eye disease (total n=13,057) 
Lu et al (2010) 
Australian Twin Study 
(BATS and TEST) 
1714 (786 
families) 
544.3 (35) 381.5-679.5 21.4 
(12.6) 
5-90 56% Illumina HumanHap 610W 
Quad 
Y 1.02 
UK Twin Study 1759 (1,119 
families) 
545.8 (34) 369-657.5 54 (12) 16-82 88.9% Illumina Hap610w 
+HumanHap 300K Duo 
Y 1.02 
BMES DNA pools 143 thin CCT 
+ 146 thick 
CCT 
Thin group: 495.52 (12.2)  
Thick group: 584.83 (13.6) 
73.95 
(7.5)  
60-95 57.3% Illumina Human 1M-Duo V3 N 1.01 
Adelaide blood pools 106 thin CCT 
+ 105 thick 
CCT 
Thin group:  488.1 (17.9) 
Thick group: 600.1 (21.9) 
70.76 
(13.3) 
25-93 55.5% Illumina Human 1M-Duo V3 N 1.00 
Vitart et al 
(2010) 
CROTIA_Vis 596 561.2 (34.6)  445-670 56.2 
(14.2) 
18-86 59.7% Illuminia HumanHap 300v1 Y 1.01 
CROTIA_Korcula 849 555.6 (36.0) 457-700 56.3 
(13.65) 
18-98 64.9% Illumina HumanHap 
370CNV-Quad 
Y 1.02 
CROTIA_Split 349 561 (36.3) 457-662 49.9 
(14.2) 
18-85 55.6% Illumina 370CNV-Quadv3 Y 1.00 
ORCADES 475 536 (33.4) 430-668 54.4 
(13.6) 
22-83 57.7% Illumina HumanHap 300v2 + 
370CNV-Quad 
Y 1.04 
Rotterdam 
Study 
RS-I 872 544.7 (35.27) 433-695 75.93 56-100 
 
50.1% Illumina Infinium II 
HumanHap550chip v3.0  
Y 1.01 
RS-II 683 549.2 (33.1) 447-669 71.3 65-92 54.3% Illumina Infinium II 
HumanHap550chip v3.0  
Y 1.01 
Western 
Australia RAINE 
study 
RAINE 886 537.9 (32.26) 417-647 17 18-22 48.8% Illumina 660 Quad  Y 1.01 
DeCODE study 
DeCODE controls 299 543 (43) 440-682 69 (9) 50-92 58.9% Illumina HumanHap300 or 
HumanHapCNV370 
Y 1.01 
Gutenberg 
Health Study 
GHS I 2796 551.4 (34.6) 442-676 55.9 
(10.9) 
35 - 74 49.0% Affymetrix Whole genome 
Human SNP array 6.0 
Y 1.03 
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GHS II 1135 562.0 (34.0) 412-675 55.0 
(10.8) 
35 - 74 50.2% Affymetrix Whole genome 
Human SNP array 6.0 
Y 1.02 
NEIGHBOR NEIGHBOR controls 144 557.74 (33.81) 475.5-656.5 62.08 (10.54)  
35-96 51.1% Illumina 
Human660W_Quad_v1 
N 1.01 
Set 2. Samples with Asian ancestries and unaffected with eye disease (total n=6,963)  
Vithana et al 
(2010) 
SINDI (Indians) 2538 539.68 (36.19)  442-1015 58.04 
(10.01) 
43 - 84 48.86
% 
Illumina Human610-Quad  Y 1.04 
SiMES (Malays) 2542 540.66 (33.56)  421-681 59.09 
(11.04) 
40 - 80 50.55
% 
Illumina Human610-Quad  Y 1.06 
Cornes et al 
(2011) 
SCES (Chinese) 1883 552.63 (33.39)  397-689 58.9 
(9.63) 
44 - 86 49.01
% 
Illumina Human610-Quad  Y 1.02 
Set 3. Glaucoma patients with European ancestries (total n=1,936)  
ANZRAG ANZRAG POAG patients 
363 514 (41.5)  347-665 60 (14.5) 11-90 53% Illumina Human1M-Omni 
arrays 
Y 1.01 
GLAUGEN 
GLAUGEN POAG 
patients 
305 542.65 (35.24) 450-673.5 62.4 
(11.2) 
40-87 60% Illumina 
Human660W_Quad_v1 
N 1.01 
NEIGHBOR NEIGHBOR POAG patients 
668 547.37(36.06)  450-647 61.09 
(13.55)  
25-92 53% Illumina 
Human660W_Quad_v1 
N 1.00 
DeCODE Study DeCODE glaucoma cases 
409 536 (42) 330 - 647 74.9 
(9.9) 
37-100 52.3% Illumina HumanHap300 or 
HumanHapCNV370 
Y 1.03 
UK South 
Hampton Study 
South Hampton POAG 
cases 
191 534.45(34.2)  416.5-623.5 73.94 37.4-95.8 48.69
% 
Affymetrix SNP 6.0 array N 1.00 
Set 4. Glaucoma patients with Asian ancestries (n=198)  
HongKong 
Study 
Normal tension 
glaucoma patients 
(Chinese) 
198 536.9 (34.5) 445-649 64.1 
(12.8) 
22-87 50.5% Illumina CNV370Quad N 1.00 
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Supplementary Table 2. Proxies of Table 1 CCT-loci.  
 
Leading SNP Proxya Distance R2 D' Arraysb 
Meta-analysis P in 
Set 1 
rs10189064 
    
I3,I5,I6,I6Q,IM,IMD,IC,ICQ,AxM,IWQ 1.01E-08 
 
rs10178538 288468 1 1 I3,I5,I6,I6Q,IM,IMD,IC,ICQ,OQ,IWQ 1.57E-06 
rs3749260 
    
I2,I5,I6,I6Q,IM,IMD,AxM,IWQ 1.26E-08 
 
rs1870717 17808 0.941 1 A6 1.14E-06 
 
rs13069468 21889 0.941 1 I5,I6,I6Q,IM,IMD,CYT,OQ,IWQ,OE 3.35E-06 
rs9822953 
    
Imputed 2.70E-08 
 
rs6441091 98491 0.848 0.921 I3,I5,I6,I6Q,IM,IMD,IC,ICQ,CM,IWQ 5.39E-06 
 
rs6807894 99894 0.848 0.921 I2,I5,I6,I6Q,IM,IMD,OQ,AxM,IWQ,OE 3.88E-06 
 
rs9852504 101358 0.848 0.921 AS,A6 3.90E-04 
 
rs7617108 102116 0.848 0.921 AN,A5,A6 3.03E-06 
 
rs13092225 116667 0.848 0.921 I2,I5,I6,I6Q,IM,IMD,CYT,OQ,IWQ,OE 3.58E-05 
rs1117707 
    
Imputed 8.40E-11 
 
rs10434530 13317 1 1 OQ,AxM,OE 8.50E-10 
 
rs1159105 31775 0.751 0.883 AS,A5,A6,OQ,AxM,OE 4.24E-10 
rs3118520 
    
I6,IM,IMD,CYT,OQ,OE 3.37E-20 
 
rs1536482 1067 0.853 1 I3,I5,I6,I6Q,IM,IMD,IC,ICQ,IWQ 6.29E-19 
 
rs3132306 1383 0.853 1 A6 8.89E-20 
 
rs3118516 1803 0.853 1 A6,I1 1.94E-19 
rs7044529 
    
I3,I5,I6,I6Q,IM,IMD,IC,ICQ,OQ,IWQ,OE 1.11E-11 
 
rs6537942 8495 1 1 AS,A5,A6,CYT,OQ,OE 6.85E-11 
 
rs12554842 5356 0.748 1 A6 4.54E-09 
 
rs12554098 5558 0.748 1 I3,I5,I6,I6Q,IM,IMD,IC,ICQ,IBC,CYT,OQ,IWQ,OE 2.57E-10 
rs11145951 
    
I3,I5,I6,I6Q,IM,IMD,IC,ICQ,CYT,OQ,IWQ,OE 9.21E-12 
 
rs908839 3625 1 1 A6 1.83E-08 
 
rs7040970 1251 0.967 1 IM,IMD 3.91E-11 
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rs11790360 5983 0.811 0.931 OQ,CM 3.95E-10 
rs1034200 
    
I2,I5,I6,I6Q,IM,IMD,OQ,IWQ,OE 6.13E-10 
rs2721051 
    
I3,I5,I6,I6Q,IM,IMD,IC,ICQ,OQ,AxM,IWQ,OE 1.32E-14 
 
rs2755238 614 1 1 A6 2.86E-14 
 
rs11616662 8582 0.915 1 A6 1.96E-13 
 
rs2721043 32216 0.752 0.907 I2,I5,I6,I6Q,IM,IMD,OQ,AxM,IWQ,OE 1.01E-11 
 
rs2755237 1455 0.736 1 A6,I2,I5,I6,I6Q,IM,IMD,OQ,AxM,IWQ,OE 1.76E-11 
rs785422 
    
I3,I5,I6,I6Q,IM,IMD,IC,ICQ,OQ,IWQ,OE 1.42E-10 
 
rs785429 14347 0.786 1 AN,A5,A6,I3,I5,I6,I6Q,IM,IMD,IC,ICQ,OQ,IWQ,OE 1.71E-09 
rs6496932 
    
AN,A5,A6,I3,I5,I6,I6Q,IM,IMD,IC,ICQ,CYT,OQ,AxM,IWQ,OE 6.75E-11 
 
rs10520600 82835 0.812 1 AH,I3,I5,I6,I6Q,IM,IMD,IC,ICQ,IWQ 2.68E-09 
 
rs12901648 126151 0.81 0.947 A6,I2,I5,I6,I6Q,IM,IMD,OQ,AxM,IWQ,OE 1.42E-06 
 
rs10163187 44951 0.729 1 A6 5.45E-10 
rs2034809 
    
I3,I5,I6,I6Q,IM,IMD,IC,ICQ,OQ,IWQ,OE 7.50E-05 
rs930847 
    
AS,A5,A6,I2,I5,I6,I6Q,IM,IMD,OQ,IWQ,OE 3.73E-13 
rs752092 
    
A6,I2,I5,I6,I6Q,IM,IMD,CYT,OQ,IWQ,OE 5.87E-09 
 
rs8043243 10481 0.897 1 AG,I3,I5,I6,I6Q,IM,IMD,IC,ICQ,IWQ 9.33E-06 
rs6540223 
    
AN,A5,A6,OQ 1.27E-39 
 
rs7500824 21945 1 1 AS,A5,A6,OQ,OE 7.08E-39 
 
rs12447690 23312 0.967 1 I3,I5,I6,I6Q,IM,IMD,IC,ICQ,IWQ,OE 8.42E-37 
 
rs12448211 9077 0.78 0.929 AN,A5,A6,IM,IMD,CYT 2.59E-38 
 
rs9938149 10204 0.777 0.897 AS,A5,A6,I2,I5,I6,I6Q,IM,IMD,IWQ,OE 6.75E-37 
rs2323457 
    
A6,I3,I5,I6,I6Q,IM,IMD,IC,ICQ,IWQ 4.68E-08 
 
rs12940030 6826 1 1 I2,I5,I6,I6Q,IM,IMD,CYT,OQ,IWQ,OE 5.70E-08 
 
rs4792534 10659 1 1 AS,A5,A6 9.60E-08 
 
rs4792535 10940 1 1 I2,I5,I6,I6Q,IM,IMD,IWQ 7.22E-08 
a. The proxies are queried using SNAP (http://www.broadinstitute.org/mpg/snap/ldsearch.php). The proxies are restricted to be less than 500kb away and in 
high linkage disequilibrium (R2>0.7 in HapMap 2 CEU set) with the leading SNP. 
b. Refer to SNAP (http://www.broadinstitute.org/mpg/snap/ldsearch.php) for array abbreviations.  
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Supplementary Table 3. Association of Table 1 CCT-loci in Set 2 Asian samples.  
 
Locusa Chr 
LeadingSNP 
Or proxiesb,c 
R2,d A1,A2 
Meta analysis of SINDI (n=2,538 Indians), SIMES (n=2,542 Malays), SCES 
(n=1,883 Chinese) Same direction 
as in Set 1? 
AF1e  Beta (se) P I2 P_Het Effect directionse 
USP37 2 rs10189064  A,G Na Na Na Na Na Na Na 
GPR15 3 rs3749260  A,C 0.16,0.13,0.10 -0.00 (0.02) 0.88 62.4 0.07 +-+ Y 
TIPARP 3 rs9822953  T,C        
  rs1430408 0.87 A,G 0.44,0.79,0.81 0.04 (0.02) 0.03 32.5 0.23 ++- Y 
CWC27- ADAMTS6 5 rs1117707  A,G        
  rs264739 0.66 T,C 0.52,0.67,0.59 -0.03 (0.02) 0.11 0 0.93 --- Y 
RXRA-COL5A1 9 rs3118520  A,G        
  rs1536482 0.94 A,G 0.45,0.25,0.22 -0.08 (0.02) 8.9e-6 0 0.61 --- Y 
COL5A1 9 rs7044529  T,C 0.26,0.16,0.12 -0.05 (0.02) 0.01 61.2 0.08 --+ Y 
LCN12-PTGDS 9 rs11145951  T,C 0.58,0.80,0.85 0.04 (0.02) 0.02 28 0.25 +++ Y 
FGF9-SGCG 13 rs1034200  A,C 0.19,0.31,0.31 0.02 (0.02) 0.26 0 0.61 -++ Y 
Near FOXO1 (3’) 13 rs2721051  T,C 0.03,Na, Na -0.13(0.07) 0.08 Na Na -?? Y 
Near TJP1 (5’) 15 rs785422  T,C 0.10,0.05, Na -0.10 (0.04) 7.6e-3 0 0.54 --? Y 
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Near AKAP13 (5’) 15 rs6496932  A,C 0.40,0.35,0.31 -0.06 (0.02) 3.0e-4 0 0.55 --- Y 
LRRK1 15 rs2034809  A,G 0.45,0.76,0.78 -0.06 (0.02) 4.2e-4 0 0.44 --- Y 
LRRK1 15 rs930847  T,G 0.83,0.61,0.80 -0.11 (0.02) 3.4e-8 0 0.85 --- Y 
CHSY1 15 rs752092  A,G 0.74,0.80,0.83 -0.05 (0.02) 0.02 15.1 0.31 --+ Y 
BANP-ZNF469 16 rs6540223  T,C        
  rs9938149 0.54 A,C 0.66,0.83,0.92 0.16 (0.02) 3.1e-15 44.5 0.17 +++ Y 
HS3ST3B1-PMP22 17 rs2323457  A,C 0.34,0.50,0.44 -0.06 (0.02) 8.5e-4 0 0.45 --- Y 
a. Locus assigned to the RefSeq protein-coding gene within or near (noted near) the association signal interval (defined by linkage disequilibrium plot using a 
measure r2 > 0.9 with the leading SNP implemented in SNAP using the CEU reference). The locus was assigned to the interval defined by the two flanking 
RefSeq protein-coding genes if clearly intergenic. Novel loci for both European and Asian populations are marked in bold.  
b. Some of the leading SNPs are rare in these Asian populations, for example rs10189064 is rare in all three populations, rs2721051 is rare in SIMES and SCES, 
and rs785422 is rare in SCES. The results are listed as missing (“Na”).  
c. The search of proxies is restricted to the Illumina Human610-Quad array, as it was the array used to genotype these samples.  
d. R2 between the leading SNP and its proxy is based on HapMap JPT+CHB reference. 
e. The allele frequency column (“AF1”) and effect direction column (“Effect directions”) are listed in the order of SINDI, SIMES, SCES. 
10 
 
Supplementary Table 4. Association of Table 2 CCT-loci in clinical sample sets: Set 3 (European) and Set 4 (Asian).  
 
Locusa Chr Leading SNP A1/A2 basepair 
  Set 3 – POAG cases (European) (N=1,936) Set 4 - NTG cases (Asian) (N=194)d 
  AF1 Beta Se P Same dir?c AF1 Beta Se P Same dir?c 
COL8A2 1 rs96067 A/G 36344507  0.811 0.027 0.043 0.529 Y 0.472 0.244 0.097 0.012 Y 
COL4A3 2 rs7606754 A/G 227843424  0.333 -0.008 0.038 0.830 Y Na Na Na Na Na 
FNDC3B 3 rs4894535 T/C 173478299  0.163 -0.019 0.047 0.687 Y 0.335 -0.127 0.108 0.241 Y 
TBL1XR1-KCNMB2b 3 rs7620503 T/C 178786992  0.395 -0.037 0.039 0.341 Y Na Na Na Na Na 
NR3C2 4 rs3931397 T/G 149298947  0.071 -0.075 0.078 0.338 Y 0.078 0.061 0.196 0.756 N 
ADAMTS6 5 rs2307121 T/C 64661268  0.340 0.103 0.034 0.002 Y 0.177 0.081 0.128 0.527 Y 
FAM46A-IBTK 6 rs1538138 T/C 82851313  0.262 -0.109 0.039 0.005 Y 0.283 -0.136 0.111 0.222 Y 
VKORC1L1 7 rs11763147 A/G 64964256  0.444 0.048 0.036 0.182 Y 0.220 0.074 0.123 0.545 Y 
C7orf42 7 rs4718428 T/G 66058881  0.644 0.080 0.040 0.044 Y 0.331 0.098 0.104 0.349 Y 
MPDZ-NF1B 9 rs1324183 A/C 13547491  0.198 -0.126 0.048 0.009 Y Na Na Na Na Na 
LPAR1 9 rs1007000 T/C 112702502  0.213 0.054 0.042 0.197 Y 0.187 0.123 0.129 0.339 Y 
RXRA-COL5A1 9 rs1536482 A/G 136580349   0.347 -0.097 0.041 0.018 Y 0.220 0.052 0.121 0.670 N 
COL5A1 9 rs7044529 T/C 136707872   0.152 -0.172 0.048 3.1E-04 Y 0.131 -0.017 0.151 0.910 Y 
LCN12-PTGDS 9 rs11145951 T/C 138980085  0.496 0.080 0.038 0.035 Y 0.874 0.132 0.152 0.385 Y 
ARID5B 10 rs7090871 T/C 63500292  0.613 0.064 0.039 0.103 Y 0.611 0.114 0.102 0.266 Y 
ARHGAP20-POU2AF1 11 rs4938174 A/G 110418450  0.283 0.140 0.038 2.2E-04 Y 0.101 0.152 0.163 0.352 Y 
Near GLT8D2 (5’) 12 rs1564892 A/G 102969872  0.785 -0.100 0.085 0.238 Y Na Na Na Na Na 
FGF9-SGCG 13 rs1034200 A/C 22126691  0.266 0.096 0.039 0.014 Y Na Na Na Na Na 
Near FOXO1(3’) 13 rs2721051 T/C 40008884  0.108 -0.105 0.054 0.051 Y Na Na Na Na Na 
Near TJP1(5’) 15 rs785422 T/C 27961177  0.097 -0.038 0.058 0.518 Y Na Na Na Na Na 
SMAD3 15 rs12913547 T/C 65254561  0.784 -0.054 0.039 0.175 Y Na Na Na Na Na 
Near AKAP13 (5’) 15 rs6496932 A/C 83626571  0.183 0.016 0.042 0.705 N 0.303 -0.099 0.111 0.373 N 
LRRK1 15 rs930847 T/G 99376085   0.771 -0.061 0.039 0.118 Y Na Na Na Na Na 
CHSY1 15 rs752092 A/G 99599457   0.675 -0.065 0.035 0.062 Y Na Na Na Na Na 
BANP-ZNF469 16 rs9938149 A/C 86889141  0.613 0.129 0.037 4.6E-04 Y Na Na Na Na Na 
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HS3ST3B1-PMP22 17 rs12940030 T/C 14501741   0.713 0.049 0.037 0.189 Y Na Na Na Na Na 
a. Locus assigned to the RefSeq protein-coding gene within or near (noted near) the association signal interval (defined by linkage disequilibrium plot using a measure 
r2 > 0.9 with the leading SNP implemented in SNAP using the CEU reference). The locus was assigned to the interval defined by the two flanking RefSeq 
protein-coding genes if clearly intergenic. Additional novel loci for both European and Asian populations are marked in bold. The locus COL4A3 was suggested in a 
set of Croatian samples but that had not reached statistical significance. 
b. The leading SNP is within a validated non coding mRNA: LINC00578. 
c. Effect directions are compared with the ones reported in Table 2. “Y” indicates the effect direction is the same; “N” indicates the SNP has an opposite effect direction. 
d. Na’s in Set 4 results indicate that either the SNP is not genotyped or it is rare in these glaucoma patients with Han Chinese ancestry. 
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Supplementary Table 5. VEGAS gene-based results on meta of European samples. 
 
Chr Genea Num. SNPs Num. Permutation Start Stop Permutated P Rank Leading SNP P for leading SNP 
5 CWC27 313 1E+06 64100510 64350346 <1e-6 1 rs3797046 3.2E-10 
5 ADAMTS6 357 1E+06 64480318 64813460 <1e-6 1 rs386188 1.2E-10 
9 COL5A1 331 1E+06 136673472 136876509 3.0E-06 3 rs7044529 5.4E-12 
9 RXRA 157 1E+03 136358230 136472252 0.53 10283 rs11185717 3.8E-03 
9 PTGDS 46 1E+06 138991776 138996015 7.0E-06 6 rs11145951 1.3E-11 
9 LCN12 52 1E+06 138966588 138969770 6.1E-05 16 rs11145951 1.3E-11 
7 GUSB 40 1E+06 65063107 65084681 8.0E-06 7 rs1701760 1.6E-07 
7 VKORC1L1 43 1E+06 64975691 65057235 8.0E-06 8 rs11763147 1.8E-07 
15 CHSY1 165 1E+06 99533454 99609649 4.0E-05 12 rs752092 1.6E-08 
15 LRRK1 266 1E+05 99276982 99427840 4.5E-03 174 rs930847 9.3E-13 
15 AKAP13 610 1E+06 83724874 84093590 5.8E-05 15 rs4843049 4.5E-10 
7 RABGEF1 84 1E+06 65843077 65913883 1.1E-04 18 rs2016325 8.7E-07 
7 C7orf42 66 1E+06 66023637 66060973 4.3E-04 48 rs4718424 1.5E-05 
7 KCTD7 66 1E+06 65731379 65743252 6.4E-04 57 rs3764903 3.9E-06 
3 FNDC3B 386 1E+06 173241079 173601181 1.3E-04 19 rs6445055 9.5E-08 
15 SMAD3 253 1E+06 65145248 65274587 2.5E-04 30 rs7181556 4.8E-07 
9 LPAR1 345 1E+06 112675874 112840186 2.7E-04 33 rs1409684 1.7E-06 
2 COL4A3 308 1E+06 227737524 227887751 3.3E-04 39 rs7606754 2.8E-07 
12 GLT8D2 184 1E+06 102906894 102968045 5.6E-04 53 rs1564892 1.4E-07 
12 HCFC2 104 1E+05 102982365 103024433 0.01 365 rs1564892 1.4E-07 
13 FOXO1 157 1E+05 40027800 40138734 3.3E-03 147 rs2721051 1.5E-14 
3 GPR15 110 1E+05 99733567 99734650 4.9E-03 179 rs3749260 1.2E-08 
10 ARID5B 212 1E+05 63331448 63526709 6.3E-03 221 rs4948502 7.1E-07 
11 ARHGAP20 260 1E+05 109952975 110088661 6.4E-03 222 rs11213578 1.8E-04 
11 C11orf53 140 1E+03 110631916 110662182 0.58 11125 rs12280810 2.8E-02 
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This gene-based test was run on Set 1 meta-analysis results, therefore HapMap 2 CEU was used as the reference. 
a. The genes were selected as known loci for CCT, novel loci and their neighbouring genes (were placed together in each block of the table) identified in this 
study.  
  
1 COL8A2 40 1E+05 36333432 36338437 0.05 1241 rs7550047 2.3E-03 
1 ADPRHL2 35 1E+05 36327072 36332120 0.06 1405 rs7550047 2.3E-03 
1 TRAPPC3 49 1E+05 36374759 36387654 0.09 1912 rs7550047 2.3E-03 
4 NR3C2 384 1E+03 149219364 149583093 0.16 3314 rs3931397 3.6E-06 
16 ZNF469 70 1E+03 87021379 87034666 0.18 3599 rs8051284 2.3E-03 
16 BANP 111 1E+03 86542538 86668425 0.39 7611 rs9924813 3.0E-03 
13 FGF9 110 1E+03 21143874 21174186 0.27 5383 rs7317531 3.5E-02 
3 TBL1XR1 149 1E+03 178221235 178397742 0.38 7407 rs9841983 3.5E-02 
3 KCNMB2 457 1E+03 179736917 180044911 0.73 13783 rs6789294 0.01 
15 TJP1 134 1E+03 27779648 27901998 0.43 8284 rs939980 7.1E-04 
6 IBTK 134 1E+03 82936674 83014167 0.47 8995 rs10943857 9.0E-05 
6 FAM46A 153 1E+03 82512165 82519147 0.48 9167 rs194914 4.9E-02 
2 USP37 101 1E+03 219023217 219141328 0.63 11948 rs10189064 1.6E-08 
17 HS3ST3B1 156 1E+03 14145230 14190217 0.64 12193 rs3848445 5.8E-03 
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Supplementary Table 6. VEGAS-Pathway analysis results on meta of European samples. 
 
GO_ID GO_term Pa Genes 
GO:00
05581 
collagen 1.0E-05 
(0.046) 
COL16A1,COL9A2,COL24A1,COL11A1,COL5A2,COL4A3,COL6A3,COL7A1,COL8A1,LOX,TNXB,COL11A2,COL9A1,COL12A1,COL10A1,
COL1A2,COL14A1,COL15A1,COL27A1,COL5A1,COL13A1,COL2A1,LUM,COL4A2,COL1A1,COL5A3,COL9A3,COL6A1 
GO:00
31012 
extracellular 
matrix 
3.2E-05 
(0.15) 
VWA1,MFAP2,WNT4,MATN1,COL16A1,COL8A2,COL9A2,LEPRE1,PODN,COL24A1,F3,COL11A1,NTNG1,WNT2B,ADAMTSL4,RPTN,B
CAN,ADAMTS4,DPT,TNR,LAMC2,HMCN1,LAD1,OPTC,LAMB3,USH2A,TGFB2,WNT3A,NID1,ZP4,PXDN,MATN3,EMILIN1,LTBP1,VIT,EF
EMP1,FBLN7,COL5A2,FN1,WNT10A,COL4A3,COL6A3,GPC1,CHL1,TIMP4,WNT7A,COLQ,EFHB,CRTAP,COL7A1,DAG1,WNT5A,ADAM
TS9,COL8A1,IMPG2,CCDC80,COL6A6,MUC4,SPON2,CPZ,SOD3,ENAM,ADAMTS3,MEPE,SNCA,NPNT,PRSS12,C4orf31,SPOCK3,ADA
MTS16,ADAMTS12,SLC1A3,EGFLAM,FGF10,ERBB2IP,THBS4,HAPLN1,LOX,FBN2,ADAMTS19,TGFBI,SPOCK1,WNT8A,RELL2,FGF1,SPA
RC,GABRA6,ADAMTS2,GPLD1,C6orf15,TNXB,COL11A2,VEGFA,CRISP3,TINAG,DST,COL9A1,COL12A1,IMPG1,LAMA4,COL10A1,LAM
A2,CTGF,SERAC1,SMOC2,COL28A1,VWC2,ELN,ZP3,TFPI2,COL1A2,GPC2,EMID2,RELN,LAMB4,WNT2,WNT16,PTPRZ1,PRSS2,LPL,M
MP16,MATN2,CTHRC1,NOV,COL14A1,OC90,FREM1,ADAMTSL1,MAMDC2,ECM2,COL15A1,COL27A1,TNC,OLFML2A,LAMC3,NTNG
2,ADAMTSL2,COL5A1,ENTPD2,UCMA,RBP3,COL13A1,ADAMTS14,SPOCK2,SFTPD,MMRN2,CRTAC1,WNT8B,KAZALD1,COL17A1,SM
C3,TECTB,FGFR2,MMP21,MUC5AC,MMP26,SPON1,NAV2,CD44,HSD17B12,ZP1,FLRT1,CD248,WNT11,MMP13,TECTA,ADAMTS15,
WNT5B,VWF,MFAP5,GRIN2B,MGP,ADAMTS20,COL2A1,WNT1,MMP19,DCN,NTN4,MMP17,FGF9,POSTN,FREM2,GPC6,COL4A2,AN
G,MMP14,COCH,NID2,BMP4,LGALS3,SMOC1,PAPLN,LTBP2,TGFB3,FLRT2,FBLN5,SERPINA1,THBS1,MFAP1,FBN1,ANXA2,CILP,THSD
4,LOXL1,ADAMTS7,ADAMTSL3,HAPLN3,ADAMTS17,PCSK6,NTN3,MMP25,OTOA,SPN,PRSS36,MMP2,MMP15,GFOD2,ADAMTS18,
CRISPLD2,NTN1,MFAP4,VTN,MMP28,WNT9B,CHAD,LGALS3BP,EMILIN2,LAMA1,LAMA3,ADAMTSL5,ADAMTS10,COL5A3,CALR,PO
DNL1,CILP2,APLP1,SPINT2,LTBP4,TGFB1,FLRT3,MMP24,EMILIN3,PI3,MMP9,BMP7,LAMA5,COL9A3,ADAMTS5,SOD1,TFF3,COL6A2
,DGCR6,MMP11,TFIP11,EMID1,TIMP3,LGALS1,WNT7B 
GO:00
05578 
proteinaceous 
extracellular 
matrix 
4.6E-05 
(0.21) 
VWA1,MFAP2,WNT4,MATN1,COL16A1,COL8A2,COL9A2,LEPRE1,PODN,COL24A1,COL11A1,NTNG1,WNT2B,ECM1,RPTN,BCAN,AD
AMTS4,DPT,TNR,LAMC2,HMCN1,LAD1,OPTC,LAMB3,USH2A,WNT3A,NID1,ZP4,MATN3,EMILIN1,LTBP1,VIT,EFEMP1,FBLN7,COL5A2
,FN1,WNT10A,COL4A3,COL6A3,GPC1,CHL1,TIMP4,WNT7A,COLQ,EFHB,CRTAP,COL7A1,DAG1,WNT5A,ADAMTS9,COL8A1,IMPG2,C
CDC80,COL6A6,MUC4,SPON2,CPZ,ENAM,ADAMTS3,MEPE,SNCA,NPNT,SPOCK3,ADAMTS16,ADAMTS12,SLC1A3,EGFLAM,ERBB2IP,
THBS4,HAPLN1,LOX,FBN2,ADAMTS19,TGFBI,SPOCK1,WNT8A,RELL2,FGF1,SPARC,ADAMTS2,GPLD1,C6orf15,TNXB,COL11A2,VEGFA
,CRISP3,TINAG,DST,COL9A1,COL12A1,IMPG1,LAMA4,COL10A1,LAMA2,CTGF,SMOC2,COL28A1,VWC2,ELN,ZP3,TFPI2,COL1A2,GPC
2,EMID2,RELN,LAMB4,WNT2,WNT16,PTPRZ1,MMP16,MATN2,CTHRC1,TNFRSF11B,COL14A1,OC90,FREM1,ADAMTSL1,MAMDC2,
15 
 
ECM2,COL15A1,COL27A1,TNC,LAMC3,NTNG2,ADAMTSL2,COL5A1,ENTPD2,UCMA,RBP3,COL13A1,ADAMTS14,SPOCK2,SFTPD,M
MRN2,CRTAC1,WNT8B,KAZALD1,COL17A1,SMC3,TECTB,MMP21,MUC5AC,MMP26,SPON1,NAV2,ZP1,FLRT1,CD248,WNT11,MMP
13,TECTA,ADAMTS15,WNT5B,VWF,MFAP5,MGP,ADAMTS20,COL2A1,WNT1,MMP19,DCN,NTN4,MMP17,FGF9,POSTN,FREM2,GPC
6,COL4A2,ANG,MMP14,COCH,NID2,BMP4,LGALS3,SMOC1,PAPLN,LTBP2,FLRT2,FBLN5,SERPINA1,MFAP1,FBN1,ANXA2,CILP,THSD4
,LOXL1,ADAMTS7,ADAMTSL3,HAPLN3,ADAMTS17,NTN3,MMP25,OTOA,SPN,PRSS36,MMP2,MMP15,GFOD2,ADAMTS18,NTN1,M
FAP4,VTN,MMP28,WNT9B,CHAD,LGALS3BP,EMILIN2,LAMA1,LAMA3,ADAMTSL5,ADAMTS10,COL5A3,CALR,PODNL1,CILP2,APLP1,
LTBP4,TGFB1,FLRT3,MMP24,EMILIN3,PI3,MMP9,LAMA5,COL9A3,ADAMTS5,TFF3,COL6A2,DGCR6,MMP11,TFIP11,EMID1,TIMP3,L
GALS1,WNT7B 
GO:00
44420 
extracellular 
matrix part 
5.0E-05
(0.23) 
VWA1,MFAP2,HSPG2,COL16A1,COL8A2,COL9A2,COL24A1,COL11A1,LAMC2,HMCN1,LAD1,LAMB3,USH2A,NID1,COL5A2,COL4A3,
COL6A3,COLQ,COL7A1,DAG1,COL8A1,CCDC80,AMTN,SNCA,PRSS12,SLC1A3,EGFLAM,ERBB2IP,LOX,RELL2,SPARC,GABRA6,TNXB,C
OL11A2,VEGFA,TINAG,DST,COL9A1,COL12A1,LAMA4,COL10A1,LAMA2,SMOC2,COL28A1,VWC2,COL1A2,ACHE,LAMB4,COL14A1,F
REM1,COL15A1,COL27A1,TNC,LAMC3,COL5A1,ENTPD2,COL13A1,MMRN2,COL17A1,SMC3,MUC5AC,EFEMP2,MFAP5,GRIN2B,COL
2A1,LUM,NTN4,FGF9,FREM2,COL4A2,ANG,NID2,SMOC1,PAPLN,MFAP1,FBN1,ANXA2,CILP,SPN,NTN1,MFAP4,COL1A1,TIMP2,LAM
A1,LAMA3,COL5A3,APLP1,LAMA5,COL9A3,ADAMTS1,TFF3,COL6A1,TIMP3 
GO:00
05583 
fibrillar 
collagen 
5.2E-05 
(0.24) 
COL11A1,COL5A2,TNXB,COL11A2,COL1A2,COL5A1,COL2A1,LUM,COL1A1,COL5A3 
GO:00
30199 
collagen fibril 
organization 
0.0002 
(0.92) 
COL11A1,DPT,TGFB2,COL5A2,ADAMTS3,LOX,ADAMTS2,FOXC1,COL11A2,COL12A1,COL1A2,COL14A1,TGFBR1,LMX1B,COL5A1,SER
PINH1,COL2A1,LUM,ANXA2,FOXC2,NF1,COL1A1,COL5A3 
GO:00
44236 
multicellular 
organismal 
metabolic 
process 
0.0002 
(0.92) 
COL3A1,TIPARP,ADAMTS3,GHR,ADAMTS2,TNXB,TRAM2,PRSS2,MMP16,CEL,COL5A1,ADAMTS14,MMP26,SERPINH1,MMP13,APOA4,M
MP19,PLA2G1B,P2RX7,MNAT1,HIF1A,MMP2,ACACA,COL1A1,ACE,PRTN3,PEPD,KLK6,MMP9,MMP11 
 
GO:00
17022 
myosin binding 0.0004 
(1) 
ACTA1,CXCR4,MLPH,MYRIP,MYL3,RHOA,GPR98,STX1A,CALD1,ARFGEF1,TRIM32,MYBPC3,MYL2,ACTC1,TRPM7,RAB27A,MYL4,GIPC1,
SNAP25,MYLK2,ARFGEF2,TRIOBP 
This pathway analysis was based on the results from gene-based test which was run on Set 1 meta-analysis results. 
a. Empirical P-value from 500,000 simulations. P-values after Bonferroni correction for multiple testing were included in the brackets. 
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Supplementary Table 7. Magenta pathway analysis results on meta of European samples. 
 
GO pathway  Nominal 
Pa 
FDRa FLAGGED_GENE_NAMES 
myosin binding 3.4E-05 0.02 ACTA1,ACTC1,RHOA,CALD1,MYBPC3,SNAP25,STX1A,ARFGEF2,ARFGEF1,GIPC1,TRIM32,MYRIP,TRPM7,GPR98 
proteinaceous 
extracellular 
matrix 
5.2E-05 0.4 ACAN,AMBN,AMELX,AMELY,BGN,BMP4,CALR,CHAD,CHI3L1,COL6A1,COL6A2,COL6A3,COL8A2,COL9A1,COL9A2,COL9A3,COL
12A1,COL16A1,COL19A1,COMP,HAPLN1,VCAN,CTGF,DAG1,DCN,COCH,DMP1,DPT,EPYC,DSPP,ECM2,ECM1,ELN,FBLN1,FBLN2,
FBN1,FBN2,EFEMP1,GPC4,FGF1,GPC5,FMOD,FN1,GPC3,GPC1,GPLD1,IMPG1,KAL1,LGALS1,LGALS3,LGALS3BP,LOXL1,LTBP1,LT
BP2,LUM,MATN1,MATN2,MATN3,MFAP1,MFAP2,MFAP4,MGP,MMP1,MMP2,MMP3,MMP7,MMP8,MMP9,MMP10,MMP11,
MMP12,MMP13,MMP16,MMP17,MMP19,MUC4,NTN3,OMD,OGN,TNFRSF11B,VIT,SERPINA1,PI3,PRELP,RELN,PTPRZ1,SFTPD,
SPARC,SPOCK1,TECTB,TECTA,TFF3,TGFB1,TGFBI,TIMP1,TIMP4,TNR,TNXB,COL14A1,VEGFA,VTN,VWF,WNT1,WNT2,WNT3,WNT5
A,WNT6,WNT7A,WNT7B,WNT8A,WNT8B,WNT10B,WNT11,WNT2B,WNT9A,WNT9B,ZP2,ZP3,PXDN,TFPI2,MFAP5,DGCR6,SPAR
CL1,LTBP4,CILP,MMP23B,CPZ,MMP20,ADAMTS4,ADAMTS3,ADAMTS2,ADAMTSL2,SPOCK2,GPC6,ENAM,LAMC3,CRISP3,SPO
N2,SPON1,CRTAP,FBLN5,POSTN,CHL1,MMP24,KERA,ADAMTS13,ADAMTS8,ADAMTS5,EMILIN1,ADAMTS7,ADAMTS6,NTNG1,
ZP1,FLRT3,FLRT2,FLRT1,TFIP11,OPTC,SPOCK3,IMPG2,ANGPTL4,WNT16,WNT4,ASPN,CRTAC1,MMP26,MEPE,ADAMTS9,CD248
,ADAMTSL3,ZP4,HAPLN2,NYX,BCAN,TNN,MMP27,LEPRE1,MMP25,MMP28,THSD4,PODNL1,ADAMTS20,WNT10A,WNT5B,GF
OD2,COL21A1,ADAMTS12,ADAMTS10,EMILIN2,FBN3,NTNG2,WNT3A,EMILIN3,ADAMTSL1,CTHRC1,RPTN,PODN,EMID1,FBLN
7,COL6A6,EMID2,ADAMTS14,HAPLN3,OTOA,PRSS36,CILP2,CHADL,ADAMTS15,ADAMTS16,ADAMTS17,ADAMTS18,ADAMTS1
9,UCMA,GPC2,NPNT,COL6A5,LAMA1,ADAMTSL5,AMTN,HAPLN4,SFTPA1,SFTPA2,OC90 
integrin binding 1.0E-04 0.4 ACTN4,ACTN1,ACTN2,ACTN3,ADAM10,DST,CALR,COL3A1,COL3A1,COL4A3,COL4A3,COL5A1,COL16A1,CTGF,DMP1,ECM2,FCE
R2,ADAM2,ICAM1,ICAM2,ICAM3,ICAM4,ILK,ITGA6,ITGA1,ITGA2,ITGA5,ITGB3,ITGB6,L1CAM,LAMA5,LYN,ADAM11,MFGE8,SY
K,ADAM17,TGFBI,THBS1,THBS4,THY1,TIMP2,TNXB,VCAM1,VWF,LTBP4,ADAM23,ADAM9,ADAM9,ADAM9,EDIL3,GPNMB,FBLN
5,CD226,ADAMTS13,ADAMTS8,ADAMTS5,NISCH,EGFL6,ADAMDEC1,ANGPTL3,ADAM22,ERBB2IP,TNN,FERMT3 
integral to 
endoplasmic 
reticulum 
membrane 
3.1E-03 1 AMFR,ASPH,BNIP1,CLN3,ERN1,EXT1,G6PC,HSPA5,RRBP1,RTN1,RTN2,SSR3,STIM1,UPK2,WFS1,DPM2,SGPL1,EDEM1,PIGK,DH
RS9,DOLK,SACM1L,SLC35D1,LRIT1,BSCL2,SPCS1,SEC61A1,DERL2,PIGT,DPM3,ACER3,SELS,RTN4,ASPHD2,DOLPP1,PORCN,ELO
VL6,DERL1,DERL3,PIGU,ASPHD1,MBOAT4 
blood vessel 
development 
4.8E-03 1 AGT,AKT1,ATP7A,CDX2,CDX4,CHM,COL1A1,COL1A2,COL3A1,COL5A1,CRKL,DHCR7,DLX3,FOXC1,FOXC2,FOXS1,FOXO1,GJA4,GJ
A5,ITGAV,LAMA4,LMO2,LOX,PKD1,PROP1,PSEN1,PTK2,TBX3,TCF7L2,TGFBR2,PPAP2B,CITED2,JMJD6,EGFL7,CHD7,MIB1,ESX1 
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metallopeptidas
e activity 
5.2E-03 1 ACY1,ADAM8,ADAM10,ADAM10,ANPEP,BMP1,CPA1,CPA2,CPA3,CPB1,CPB2,CPD,CPE,CPM,CPN1,ACE,ACE,FOLH1,ADAM2,LN
PEP,LTA4H,ADAM11,MME,PAPPA,PAPPA,CHMP1A,ADAM17,TAF2,ZNF708,ADAM12,MMP23B,CPZ,ADAM23,ADAM21,ADAM2
0,ADAM18,ADAM15,ADAM9,RPS6KA5,ECEL1,ADAMTS4,ADAMTS2,ADAMTS1,NPEPPS,NAALAD2,NAALADL1,DPP3,PSMD14,P
GCP,STAMBP,ADAM28,COPS5,ADAM30,ADAM29,ADAMTS13,ADAMTS8,ADAMTS5,ADAMTS7,ADAMTS6,AGTPBP1,DNPEP,TR
HDE,CPA4,AMZ2,YBEY,CNDP2,CPXM1,ADAMTS9,CPA6,RNPEPL1,ADAMTSL3,TMEM27,STAMBPL1,ACE2,PAPPA2,XPNPEP3,ERA
P2,BRCC3,AGBL2,ERMP1,CNDP1,AGBL4,C9orf3,XRCC6BP1,CPA5,MYSM1,AGBL1,CPO,ZFP90,AMZ1,AQPEP,FOLH1B,AGBL3 
heme binding 0.01 1 AMBP,CAT,CBS,CBS,CYB5A,CYBA,CYBB,CYC1,CYP1A1,CYP1A2,CYP1B1,CYP2A6,CYP2A7,CYP3A7,CYP2A13,CYP2B6,CYP2C19,CY
P2C8,CYP2C9,CYP2C18,CYP2D6,CYP2E1,CYP2F1,CYP2J2,CYP3A4,CYP3A5,CYP4A11,CYP4B1,CYP7A1,CYP8B1,CYP11A1,CYP11B
1,CYP11B2,CYP17A1,CYP19A1,CYP21A2,CYP24A1,CYP26A1,CYP27A1,CYP27B1,CYP51A1,DOCK2,GUCY1A2,GUCY1A3,GUCY1
B3,HBA2,HBM,HBB,HBD,HBE1,HBG1,HBG2,HBQ1,HBZ,HMOX1,IDO1,FADS1,FADS3,LPO,CYP4F3,MB,MPO,NOS1,NOS2,NOS3,
PTGIS,PTGS1,PTGS2,SDHC,SDHD,SUOX,TBXAS1,TDO2,TPO,PXDN,EPX,CYP4F2,HERC2,FADS2,CYP7B1,PGRMC2,PGRMC1,CYP46
A1,CYP4F8,EIF2AK1,CYP2S1,NENF,DUOX2,NOX4,HEBP1,CYB5R4,CYP39A1,DUOX1,CYCS,CYP2W1,CYP26B1,CYP20A1,CYP4F11,
NGB,CYP3A43,CYP4F12,FA2H,NOX5,CYB5B,CYP2U1,CYGB,CYP2R1,CYB5D1,CYB5D2,CYP4F22,PXDNL,CYP4Z2P,IDO2,CYP4Z1,C
YP4X1,CYP4A22,CYP4V2,CYP27C1,CYP26C1 
collagen 0.01 1 COL1A1,COL1A2,COL2A1,COL3A1,COL4A1,COL4A2,COL4A3,COL4A4,COL4A6,COL5A1,COL5A2,COL10A1,COL11A1,COL11A2,C
OL19A1,LOX,COL14A1,COL5A3,COL18A1,COL27A1,COL24A1 
acyl-CoA 
dehydrogenase 
activity 
0.02 1 ACADM,ACADM,ACADS,ACADSB,ACOX1,ACOX2,ACOX3,ACAD8,ACAD9,ACOXL,ACAD10,ACAD11 
T cell activation 0.02 1 ADA,CBLB,CD2,CD3E,CD3G,CD7,CD8A,CD8B,CD80,CD86,CD48,DDOST,DPP4,FKBP1A,HSPD1,IFNAR1,IRF4,SMAD3,NCK1,PRLR,
VAV1,WAS,NCK2,TNFSF14,KIF13B,ICOSLG,FOXP3,CLEC7A,TREML2,CD276,SLA2,HSH2D,NLRC3 
The Magenta pathway analysis was based on the results from gene-based test which was run on Set 1 meta-analysis results. 
a. Used the 95 percentile of all gene scores as enrichment cutoff. 
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Supplementary Table 8. VEGAS-Pathway analysis results on meta of Asian samples. 
 
GO_ID GO_term Pa Genes 
GO:00
30199 
collagen fibril 
organization 
3.8E-0
5 
(0.17) 
COL11A1,DPT,TGFB2,COL5A2,ADAMTS3,LOX,ADAMTS2,FOXC1,COL11A2,COL12A1,COL1A2,COL14A1,TGFBR1,LMX1B,COL5A1,SERPINH1,COL2
A1,LUM,ANXA2,FOXC2,NF1,COL1A1,COL5A3 
 
GO:00
30198 
extracellular 
matrix 
organization 
4.6E-0
5 
(0.21) 
VWA1,HSPG2,COL8A2,CYR61,COL11A1,DPT,TNR,LAMC1,ELF3,TGFB2,AGT,NID1,PXDN,MPV17,COL5A2,COL4A3,VHL,CCDC80,APBB2,PDGFRA,A
DAMTS3,IBSP,C4orf31,EGFLAM,LOX,TGFBI,SPINK5,B4GALT7,ADAMTS2,FOXC1,C6orf15,TNXB,COL11A2,COL19A1,COL12A1,SERAC1,COL1A2,CS
GALNACT1,TNFRSF11B,COL14A1,PTK2,B4GALT1,RECK,ECM2,TGFBR1,OLFML2A,LMX1B,POMT1,COL5A1,ITGA8,SPOCK2,KAZALD1,NFKB2,MUC
5AC,ILK,WT1,HSD17B12,SERPINH1,MPZL3,APLP2,ADAMTS20,COL2A1,MYF5,DCN,POSTN,COL4A2,LGALS3,ANXA2,MYH11,GFOD2,CRISPLD2,FO
XC2,VMO1,VTN,NF1,COL1A1,COL5A3,APLP1,MIA,BCL3,ERCC2,FKBP1A,CST3,MMP9,APP,COL18A1,COL6A2,TMPRSS6 
GO:00
44420 
extracellular 
matrix part 
5.4E-0
5 
(0.25) 
VWA1,MFAP2,HSPG2,COL16A1,COL8A2,COL9A2,COL24A1,COL11A1,LAMC2,HMCN1,LAD1,LAMB3,USH2A,NID1,COL5A2,COL4A3,COL6A3,COL
Q,COL7A1,DAG1,COL8A1,CCDC80,AMTN,SNCA,PRSS12,SLC1A3,EGFLAM,ERBB2IP,LOX,RELL2,SPARC,GABRA6,TNXB,COL11A2,VEGFA,TINAG,DS
T,COL9A1,COL12A1,LAMA4,COL10A1,LAMA2,SMOC2,COL28A1,VWC2,COL1A2,ACHE,LAMB4,COL14A1,FREM1,COL15A1,COL27A1,TNC,LAMC3
,COL5A1,ENTPD2,COL13A1,MMRN2,COL17A1,SMC3,MUC5AC,EFEMP2,MFAP5,GRIN2B,COL2A1,LUM,NTN4,FGF9,FREM2,COL4A2,ANG,NID2,S
MOC1,PAPLN,MFAP1,FBN1,ANXA2,CILP,SPN,NTN1,MFAP4,COL1A1,TIMP2,LAMA1,LAMA3,COL5A3,APLP1,LAMA5,COL9A3,ADAMTS1,TFF3,CO
L6A1,TIMP3 
GO:00
60325 
face 
morphogene
sis 
1.9E-0
4 
(0.87) 
CSRNP1,TIPARP,PDGFRA,ASPH,ARID5B,SGPL1,PLEKHA1,MMP2,COL1A1 
GO:00
05201 
extracellular 
matrix 
structural 
constituent 
1.9E-0
4 
(0.87) 
WNT4,MATN1,TINAGL1,COL8A2,COL9A2,COL24A1,COL11A1,TUFT1,LAMC1,OPTC,WNT3A,PXDN,MATN3,EMILIN1,COL5A2,FN1,WNT6,COL4A3
,FBLN2,IMPG2,MUC4,STATH,ENAM,MEPE,FBN2,COL11A2,COL9A1,COL12A1,IMPG1,LAMA4,ELN,TFPI2,COL1A2,MUC17,LAMB1,WNT2,WNT16,
COL14A1,COL15A1,COL27A1,COL5A1,COL13A1,MUC5AC,EFEMP2,CD4,MFAP5,MGP,COL2A1,LUM,COL4A2,FBN1,ACAN,WNT9B,CHAD,EMILIN
2,LAMA1,FBN3,COL5A3,COMP,COL9A3,COL18A1,COL6A2,FBLN1 
GO:00
05801 
cis-Golgi 
network 
2.6E-0
4 (1) 
TRAPPC3,PHTF1,GOLIM4,MAP6D1,FAM134B,HOOK3,SCYL1,TRAPPC4,DNM1L,COG3,SCFD1,TMED10,GOLGA5,TRAPPC1,GOSR1,COPZ2,KIAA10
12,TRAPPC5 
GO:00
31012 
extracellular 
matrix 
4.2E-0
4 (1) 
VWA1,MFAP2,WNT4,MATN1,COL16A1,COL8A2,COL9A2,LEPRE1,PODN,COL24A1,F3,COL11A1,NTNG1,WNT2B,ADAMTSL4,RPTN,BCAN,ADAMT
S4,DPT,TNR,LAMC2,HMCN1,LAD1,OPTC,LAMB3,USH2A,TGFB2,WNT3A,NID1,ZP4,PXDN,MATN3,EMILIN1,LTBP1,VIT,EFEMP1,FBLN7,COL5A2,F
N1,WNT10A,COL4A3,COL6A3,GPC1,CHL1,TIMP4,WNT7A,COLQ,EFHB,CRTAP,COL7A1,DAG1,WNT5A,ADAMTS9,COL8A1,IMPG2,CCDC80,COL6A
19 
 
6,MUC4,SPON2,CPZ,SOD3,ENAM,ADAMTS3,MEPE,SNCA,NPNT,PRSS12,C4orf31,SPOCK3,ADAMTS16,ADAMTS12,SLC1A3,EGFLAM,FGF10,ERBB
2IP,THBS4,HAPLN1,LOX,FBN2,ADAMTS19,TGFBI,SPOCK1,WNT8A,RELL2,FGF1,SPARC,GABRA6,ADAMTS2,GPLD1,C6orf15,TNXB,COL11A2,VEGF
A,CRISP3,TINAG,DST,COL9A1,COL12A1,IMPG1,LAMA4,COL10A1,LAMA2,CTGF,SERAC1,SMOC2,COL28A1,VWC2,ELN,ZP3,TFPI2,COL1A2,GPC2,E
MID2,RELN,LAMB4,WNT2,WNT16,PTPRZ1,PRSS2,LPL,MMP16,MATN2,CTHRC1,NOV,COL14A1,OC90,FREM1,ADAMTSL1,MAMDC2,ECM2,COL1
5A1,COL27A1,TNC,OLFML2A,LAMC3,NTNG2,ADAMTSL2,COL5A1,ENTPD2,UCMA,RBP3,COL13A1,ADAMTS14,SPOCK2,SFTPD,MMRN2,CRTAC1,
WNT8B,KAZALD1,COL17A1,SMC3,TECTB,FGFR2,MMP21,MUC5AC,MMP26,SPON1,NAV2,CD44,HSD17B12,ZP1,FLRT1,CD248,WNT11,MMP13,
TECTA,ADAMTS15,WNT5B,VWF,MFAP5,GRIN2B,MGP,ADAMTS20,COL2A1,WNT1,MMP19,DCN,NTN4,MMP17,FGF9,POSTN,FREM2,GPC6,COL
4A2,ANG,MMP14,COCH,NID2,BMP4,LGALS3,SMOC1,PAPLN,LTBP2,TGFB3,FLRT2,FBLN5,SERPINA1,THBS1,MFAP1,FBN1,ANXA2,CILP,THSD4,LO
XL1,ADAMTS7,ADAMTSL3,HAPLN3,ADAMTS17,PCSK6,NTN3,MMP25,OTOA,SPN,PRSS36,MMP2,MMP15,GFOD2,ADAMTS18,CRISPLD2,NTN1,
MFAP4,VTN,MMP28,WNT9B,CHAD,LGALS3BP,EMILIN2,LAMA1,LAMA3,ADAMTSL5,ADAMTS10,COL5A3,CALR,PODNL1,CILP2,APLP1,SPINT2,LT
BP4,TGFB1,FLRT3,MMP24,EMILIN3,PI3,MMP9,BMP7,LAMA5,COL9A3,ADAMTS5,SOD1,TFF3,COL6A2,DGCR6,MMP11,TFIP11,EMID1,TIMP3,LG
ALS1,FBLN1 
GO:00
60323 
head 
morphogene
sis 
4.4E-0
4 (1) 
FLVCR1,CSRNP1,TIPARP,PDGFRA,ASPH,ARID5B,SGPL1,PLEKHA1,MMP2,ANKRD11,COL1A1 
This pathway analysis was based on the results from gene-based test which was run on Set 2 meta-analysis results. 
b. Empirical P-value from 500,000 simulations. P-values after Bonferroni correction for multiple testing were included in the brackets. 
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Supplementary Table 9. Top five pathways from VEGAS-Pathway analysis of meta on European and Asian samples. 
 
GO_ID GO_term Pa Genes 
GO:00
30199 
collagen fibril 
organization 
3.2E-07 
(1.5E-3) 
COL11A1,DPT,TGFB2,COL5A2,ADAMTS3,LOX,ADAMTS2,FOXC1,COL11A2,COL12A1,COL1A2,COL14A1,TGFBR1,LMX1B,COL5A1,SERPINH1,CO
L2A1,LUM,ANXA2,FOXC2,NF1,COL1A1,COL5A3 
 
GO:00
05581 
collagen 3.5E-06 
(0.016) 
COL16A1,COL9A2,COL24A1,COL11A1,COL5A2,COL4A3,COL6A3,COL7A1,COL8A1,LOX,TNXB,COL11A2,COL9A1,COL12A1,COL10A
1,COL1A2,COL14A1,COL15A1,COL27A1,COL5A1,COL13A1,COL2A1,LUM,COL4A2,COL1A1,COL5A3,COL9A3,COL6A1 
GO:00
05583 
fibrillar 
collagen 
4.8E-06 
(0.022) 
COL11A1,COL5A2,TNXB,COL11A2,COL1A2,COL5A1,COL2A1,LUM,COL1A1,COL5A3 
GO:00
44420 
extracellular 
matrix part 
5.2E-06 
(0.024) 
VWA1,MFAP2,HSPG2,COL16A1,COL8A2,COL9A2,COL24A1,COL11A1,LAMC2,HMCN1,LAD1,LAMB3,USH2A,NID1,COL5A2,COL4A3,COL6A3,C
OLQ,COL7A1,DAG1,COL8A1,CCDC80,AMTN,SNCA,PRSS12,SLC1A3,EGFLAM,ERBB2IP,LOX,RELL2,SPARC,GABRA6,TNXB,COL11A2,VEGFA,TINA
G,DST,COL9A1,COL12A1,LAMA4,COL10A1,LAMA2,SMOC2,COL28A1,VWC2,COL1A2,ACHE,LAMB4,COL14A1,FREM1,COL15A1,COL27A1,TNC,
LAMC3,COL5A1,ENTPD2,COL13A1,MMRN2,COL17A1,SMC3,MUC5AC,EFEMP2,MFAP5,GRIN2B,COL2A1,LUM,NTN4,FGF9,FREM2,COL4A2,AN
G,NID2,SMOC1,PAPLN,MFAP1,FBN1,ANXA2,CILP,SPN,NTN1,MFAP4,COL1A1,TIMP2,LAMA1,LAMA3,COL5A3,APLP1,LAMA5,COL9A3,ADAMTS
1,TFF3,COL6A1,TIMP3 
GO:00
31012 
extracellular 
matrix 
1.3E-05 
(0.06) 
VWA1,MFAP2,WNT4,MATN1,COL16A1,COL8A2,COL9A2,LEPRE1,PODN,COL24A1,F3,COL11A1,NTNG1,WNT2B,ADAMTSL4,RPTN,
BCAN,ADAMTS4,DPT,TNR,LAMC2,HMCN1,LAD1,OPTC,LAMB3,USH2A,TGFB2,WNT3A,NID1,ZP4,PXDN,MATN3,EMILIN1,LTBP1,VIT
,EFEMP1,FBLN7,COL5A2,FN1,WNT10A,COL4A3,COL6A3,GPC1,CHL1,TIMP4,WNT7A,COLQ,EFHB,CRTAP,COL7A1,DAG1,WNT5A,A
DAMTS9,COL8A1,IMPG2,CCDC80,COL6A6,MUC4,SPON2,CPZ,SOD3,ENAM,ADAMTS3,MEPE,SNCA,NPNT,PRSS12,C4orf31,SPOCK
3,ADAMTS16,ADAMTS12,SLC1A3,EGFLAM,FGF10,ERBB2IP,THBS4,HAPLN1,LOX,FBN2,ADAMTS19,TGFBI,SPOCK1,WNT8A,RELL2,F
GF1,SPARC,GABRA6,ADAMTS2,GPLD1,C6orf15,TNXB,COL11A2,VEGFA,CRISP3,TINAG,DST,COL9A1,COL12A1,IMPG1,LAMA4,COL1
0A1,LAMA2,CTGF,SERAC1,SMOC2,COL28A1,VWC2,ELN,ZP3,TFPI2,COL1A2,GPC2,EMID2,RELN,LAMB4,WNT2,WNT16,PTPRZ1,PRS
S2,LPL,MMP16,MATN2,CTHRC1,NOV,COL14A1,OC90,FREM1,ADAMTSL1,MAMDC2,ECM2,COL15A1,COL27A1,TNC,OLFML2A,LA
MC3,NTNG2,ADAMTSL2,COL5A1,ENTPD2,UCMA,RBP3,COL13A1,ADAMTS14,SPOCK2,SFTPD,MMRN2,CRTAC1,WNT8B,KAZALD1,
COL17A1,SMC3,TECTB,FGFR2,MMP21,MUC5AC,MMP26,SPON1,NAV2,CD44,HSD17B12,ZP1,FLRT1,CD248,WNT11,MMP13,TECT
A,ADAMTS15,WNT5B,VWF,MFAP5,GRIN2B,MGP,ADAMTS20,COL2A1,WNT1,MMP19,DCN,NTN4,MMP17,FGF9,POSTN,FREM2,G
PC6,COL4A2,ANG,MMP14,COCH,NID2,BMP4,LGALS3,SMOC1,PAPLN,LTBP2,TGFB3,FLRT2,FBLN5,SERPINA1,THBS1,MFAP1,FBN1,
ANXA2,CILP,THSD4,LOXL1,ADAMTS7,ADAMTSL3,HAPLN3,ADAMTS17,PCSK6,NTN3,MMP25,OTOA,SPN,PRSS36,MMP2,MMP15,G
21 
 
FOD2,ADAMTS18,CRISPLD2,NTN1,MFAP4,VTN,MMP28,WNT9B,CHAD,LGALS3BP,EMILIN2,LAMA1,LAMA3,ADAMTSL5,ADAMTS1
0,COL5A3,CALR,PODNL1,CILP2,APLP1,SPINT2,LTBP4,TGFB1,FLRT3,MMP24,EMILIN3,PI3,MMP9,BMP7,LAMA5,COL9A3,ADAMTS
5,SOD1,TFF3,COL6A2,DGCR6,MMP11,TFIP11,EMID1,TIMP3,LGALS1,WNT7B 
These results were from the meta-analysis of pathways obtained from both European and Asian samples using Fisher’s method. 
c. Empirical P-value from 500,000 simulations. P-values after Bonferroni correction for multiple testing were included in the brackets. 
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Supplementary Table 10. Key GO pathways suggested from GRAIL analysis of Table 2 Loci. 
 
GO:0030020 extracellular matrix structural constituent conferring tensile strength  
GO:0005581 collagen  
GO:0006875 metal ion homeostasis  
GO:0030003 cation homeostasis  
GO:0006873 cell ion homeostasis  
GO:0050801 ion homeostasis  
GO:0006817 phosphate transport  
GO:0005201 extracellular matrix structural constituent  
GO:0044420 extracellular matrix part  
GO:0019725 cell homeostasis  
GO:0015698 inorganic anion transport  
GO:0006820 anion transport  
GO:0005918 septate junction  
GO:0042592 homeostasis  
GO:0048522 positive regulation of cellular process  
GO:0006874 calcium ion homeostasis  
GO:0042127 regulation of cell proliferation  
GO:0048598 embryonic morphogenesis  
GO:0003707 steroid hormone receptor activity  
GO:0008283 cell proliferation  
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Supplementary Table 11. Association between CCT loci and keratoconus risk in two independent studies. 
 
Locusa Chr 
Leading SNP or its proxy 
(r2)b 
A1/A2  
South Australia samplesc  
(N case/con=652/2,761) 
 
US samplesc 
(N case/con=222/3,324) 
AF1case AF1con OR Se P   AF1case AF1con OR Se P 
 COL8A2 1 rs96067 A/G  0.78 0.80 0.86 0.07 0.04 
 
0.80 0.80 1.10 0.13 0.45 
 COL4A3 2 rs7606754 A/G 
 
0.37 0.33 1.19 0.06 6.0E-03 
 
Na Na Na Na Na 
 
  
rs7560053 (0.8) T/C  
     
0.34 0.34 0.96 0.11 0.71 
 FNDC3B 3 rs4894535 T/C  0.21 0.16 1.46 0.08 1.3E-06 
 
0.21 0.15 1.52 0.13 8.5E-04 
 TBL1XR1-KCNMB2 3 rs7620503 T/C  Na Na Na Na Na 
 
Na Na Na Na Na 
 NR3C2 4 rs3931397 T/G  0.09 0.08 1.22 0.11 0.07 
 
0.10 0.08 1.15 0.17 0.41 
 ADAMTS6 5 rs2307121 T/C  0.33 0.33 1.00 0.07 0.97 
 
0.33 0.32 1.03 0.11 0.79 
 FAM46A-IBTK 6 rs1538138 T/C  0.26 0.23 1.13 0.07 0.10 
 
0.23 0.25 0.88 0.12 0.29 
 VKORC1L1 7 rs11763147 A/G  Na Na Na Na Na 
 
0.44 0.42 1.22 0.10 0.06 
 C7orf42 7 rs4718428 T/G  Na Na Na Na Na 
 
0.28 0.29 0.78 0.12 0.03 
 MPDZ-NF1B 9 rs1324183 A/C  0.24 0.20 1.33 0.07 8.8E-05 
 
0.26 0.21 1.33 0.12 0.02 
 LPAR1 9 rs1007000 T/C  0.20 0.22 0.91 0.08 0.24 
 
0.19 0.21 0.83 0.13 0.17 
 RXRA-COL5A1 9 rs1536482 A/G  0.40 0.34 1.32 0.06 1.2E-05 
 
0.41 0.33 1.32 0.10 6.5E-03 
 COL5A1 9 rs7044529 T/C  0.18 0.14 1.34 0.08 3.0E-04 
 
0.17 0.14 1.44 0.14 7.4E-03 
 PTGDS 9 rs11145951 T/C  0.45 0.49 0.87 0.06 0.03 
 
0.45 0.48 0.84 0.10 0.09 
 ARID5B 10 rs7090871 T/C  0.58 0.58 1.00 0.06 1.00 
 
0.66 0.61 1.21 0.11 0.07 
 ARHGAP20-POU2AF1 11 rs4938174 A/G  0.29 0.30 0.95 0.07 0.43 
 
0.27 0.31 0.76 0.11 0.02 
 Near GLT8D2 (5’) 12 rs1564892 A/G  Na Na Na Na Na 
 
Na Na Na Na Na 
 FGF9-SGCG 13 rs1034200 A/C 
 
0.30 0.28 1.07 0.07 0.34 
 
Na Na Na Na Na 
 
  
rs1034198 (1) T/C  
     
0.23 0.28 0.80 0.12 0.07 
 Near FOXO1(3’) 13 rs2721051 T/C  0.14 0.10 1.53 0.09 3.2E-06 
 
0.17 0.10 1.83 0.14 9.5E-06 
 Near TJP1(5’) 15 rs785422 T/C  0.09 0.10 0.87 0.11 0.18 
 
0.11 0.11 1.09 0.16 0.60 
 SMAD3 15 rs12913547 T/C  0.81 0.79 1.18 0.08 0.03 
 
Na Na Na Na Na 
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a. Locus assigned to the RefSeq protein-coding gene within or near (noted near) the association signal interval (defined by linkage disequilibrium plot using a 
measure r2 > 0.9 with the leading SNP implemented in SNAP using the CEU reference). The locus was assigned to the interval defined by the two flanking 
RefSeq protein-coding genes if clearly intergenic. All novel loci for both European and Asian populations are marked in bold. The locus COL4A3 was 
suggested in a set of Croatian samples but that had not reached statistical significance. The locus MPDZ-NF1B was previously reported as 9p23. The locus 
FGF9-SGCG was previously reported as AVGR8. 
b. For the SNPs not genotyped in the US samples, we presented the results from its proxy.  
c. Na’s in results indicate that the SNP is not genotyped. 
 
 
 
  
  
rs4601989 (0.67) C/T  
     
0.24 0.20 1.38 0.13 0.01 
 Near AKAP13 (5’) 15 rs6496932 A/C  Na Na Na Na Na 
 
0.23 0.20 1.06 0.12 0.63 
 LRRK1 15 rs930847 T/G  0.77 0.78 0.96 0.07 0.55 
 
Na Na Na Na Na 
 CHSY1 15 rs752092 A/G 
 
0.67 0.67 0.98 0.07 0.82 
 
Na Na Na Na Na 
 
  
rs8043243 (0.9) C/T  
     
0.38 0.34 1.23 0.11 0.06 
 BANP-ZNF469 16 rs9938149 A/C  0.68 0.64 1.19 0.07 7.1E-03 
 
0.33 0.27 1.52 0.14 2.5E-3 
 HS3ST3B1-PMP22 17 rs12940030 T/C 
 
0.71 0.71 0.99 0.07 0.92 
 
Na Na Na Na Na 
 
  
rs2323457 (1) C/A  
     
0.29 0.29 1.12 0.11 0.31 
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Supplementary Table 12. Association between CCT loci and susceptibility to primary open angle glaucoma in three independent studies. 
 
Locusa Chr 
Leading 
SNP A1/A2 
GLAUGEN + NEIGHBOR 
HTGb (Ncase/con=1669/3443)   
GLAUGEN + NEIGHBOR 
NTGb (Ncase/con=720/3443)   
SouthAustralia 
(Ncase/con=590/3,956) 
OR Se P   OR Se P 
 
OR Se P 
COL8A2 1 rs96067 A/G 0.88 0.09 0.05 
 
1.03 0.12 0.77 
 
1.08 0.08 0.36 
COL4A3 2 rs7606754 A/G 0.96 0.07 0.47 
 
1.04 0.10 0.63 
 
1.02 0.07 0.79 
FNDC3B 3 rs4894535 T/C 0.81 0.10 6.9E-03 
 
0.71 0.14 1.4E-03 
 
0.85 0.09 0.08 
TBL1XR1-KCNMB2 3 rs7620503 T/C 0.91 0.07 0.10 
 
0.94 0.10 0.41 
 
0.83 0.07 0.01 
NR3C2 4 rs3931397 T/G 0.89 0.13 0.23 
 
0.81 0.19 0.10 
 
0.95 0.13 0.69 
ADAMTS6 5 rs2307121 T/C 0.94 0.08 0.27 
 
0.94 0.10 0.39 
 
0.92 0.07 0.19 
FAM46A-IBTK 6 rs1538138 T/C 0.92 0.08 0.18 
 
0.98 0.11 0.79 
 
1.02 0.07 0.75 
VKORC1L1 7 rs11763147 A/G 1.03 0.07 0.61 
 
1.04 0.10 0.63 
 
Na Na Na 
C7orf42 7 rs4718428 T/G 0.97 0.07 0.72 
 
1.11 0.10 0.30 
 
1.12 0.07 0.10 
MPDZ-NF1B 9 rs1324183 A/C 1.10 0.09 0.15 
 
1.14 0.12 0.13 
 
1.03 0.08 0.68 
LPAR1 9 rs1007000 T/C 1.01 0.09 0.91 
 
1.05 0.11 0.52 
 
0.91 0.08 0.26 
RXRA-COL5A1 9 rs1536482 A/G 1.08 0.07 0.17 
 
0.96 0.10 0.59 
 
0.92 0.09 0.35 
COL5A1 9 rs7044529 T/C 0.94 0.10 0.41 
 
1.23 0.14 0.04 
 
0.98 0.09 0.82 
LCN12-PTGDS 9 rs11145951 T/C 1.02 0.07 0.74 
 
1.02 0.10 0.83 
 
1.04 0.08 0.57 
ARID5B 10 rs7090871 T/C 0.94 0.07 0.24 
 
1.02 0.10 0.79 
 
1.08 0.08 0.31 
ARHGAP20-POU2AF1 11 rs4938174 A/G 0.93 0.08 0.23 
 
0.95 0.11 0.47 
 
0.82 0.07 6.4E-03 
Near GLT8D2 (5’) 12 rs1564892 A/G Na Na Na 
 
Na Na Na 
 
1.24 0.08 5.9E-03 
FGF9-SGCG 13 rs1034200 A/C 1.03 0.08 0.67 
 
0.90 0.11 0.20 
 
0.98 0.07 0.82 
Near FOXO1(3’) 13 rs2721051 T/C 1.05 0.12 0.57 
 
1.10 0.15 0.41 
 
1.14 0.10 0.18 
Near TJP1(5’) 15 rs785422 T/C 1.18 0.12 0.29 
 
0.92 0.16 0.67 
 
0.98 0.10 0.88 
SMAD3 15 rs12913547 T/C 1.05 0.08 0.46 
 
0.89 0.12 0.19 
 
1.00 0.08 0.97 
Near AKAP13 (5’) 15 rs6496932 A/C 1.00 0.09 0.97 
 
1.00 0.12 0.99 
 
0.92 0.08 0.33 
LRRK1 15 rs930847 T/G 1.05 0.08 0.40 
 
0.91 0.11 0.24 
 
0.97 0.07 0.71 
CHSY1 15 rs752092 A/G 1.04 0.07 0.47 
 
0.97 0.10 0.69 
 
1.06 0.07 0.38 
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BANP-ZNF469 16 rs9938149 A/C 1.00 0.07 0.96 
 
1.02 0.10 0.74 
 
Na Na Na 
HS3ST3B1-PMP22 17 rs12940030 T/C 0.98 0.08 0.77 
 
1.04 0.10 0.57 
 
1.08 0.07 0.26 
a. Locus assigned to the RefSeq protein-coding gene within or near (noted near) the association signal interval (defined by linkage disequilibrium plot using a 
measure r2 > 0.9 with the leading SNP implemented in SNAP using the CEU reference). The locus was assigned to the interval defined by the two flanking 
RefSeq protein-coding genes if clearly intergenic. All novel loci for both European and Asian populations are marked in bold. The locus COL4A3 was 
suggested in a set of Croatian samples but that had not reached statistical significance. The locus MPDZ-NF1B was previously reported as 9p23. The locus 
FGF9-SGCG was previously reported as AVGR8. 
b. “HTG” stands for high-tension glaucoma and “NTG” stands for normal-tension glaucoma.  
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Supplementary Table 13: Human and mouse corneal gene expression of CCT-associated loci. 
  
Locusa 
Expressed 
in humanb 
Expression 
Valuec 
Affymetrix 
Probe ID 
Mouse 
homologd 
Expressed 
in mouseb 
Expression 
Valuee 
Affymetrix 
Probe ID 
USP37 P 6.5 226729_at  P 8.0 1438212_at 
GPR15 A 4.3 208524_at  A 3.3 1431296_at 
CWC27 P 7.4 223337_at Sdccag10 P 8.5 1426455_at 
ADAMTS6 A 3.1 220866_at  A 3.9 1437506_at 
RXRA P 7.0 202426_s_at  P 6.0 1425762_a_at 
COL5A1 P 5.7 203325_s_at  P 9.3 1434479_at 
LCN12 A 4.3 230717_at  A 4.8 1429935_at 
PTGDS P 13.2 212187_x_at  P 8.2 1423859_a_at 
FGF9 P 6.8 206404_at  P 6.5 1420795_at 
FOXO1 P 7.8 202723_s_at  P 9.4 1416982_at 
TJP1 P 10.1 202011_at  P 12.0 1417749_a_at 
AKAP13 P 7.2 227039_at  P 8.2 1440392_at 
LRRK1 P 7.0 219441_s_at  P 9.4 1451985_at 
CHSY1 P 9.9 203044_at  P 10.3 1434316_at 
ZNF469 P 6.3 230440_at Gm22 P 6.8 1459622_at 
HS3ST3B1 A 4.2 1561908_a_at  P 5.7 1421331_at 
COL8A2 P 8.6 221900_at  P 11.2 1434667_at 
COL4A3 A 4.6 216898_s_at  P 8.4 1450224_at 
FNDC3B P 5.5 242029_at  P 9.3 1452783_at 
TBL1XR1 P 7.7 221428_s_at  P 7.6 1450739_at 
KCNMB2 P 6.1 221097_s_at  A 3.6 1426322_a_at 
NR3C2 P 7.7 205259_at  P 5.5 1435991_at 
FAM46A P 7.5 224973_at  P 10.2 1437868_at 
IBTK P 10.1 210970_s_at  P 5.8 1434282_at 
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VKORC1L1 P 7.6 224881_at  P 10.5 1429092_at 
C7orf42 P 9.5 218008_at 0610007L01Rik P 9.9 1428544_at 
LPAR1 P 6.6 204038_s_at  P 9.8 1448606_at 
ARID5B P 6.4 235404_at  P 7.3 1442176_at 
ARHGAP20 P 5.3 1555020_a_at  P 5.7 1429918_at 
GLT8D2 P 7.7 227070_at  P 7.8 1429402_at 
SMAD3 P 6.8 205397_x_at  P 6.3 1450472_s_at 
   
Microarray was performed on corneas from two human donor samples (GSE29402) and three adult inbred strains of mice (C57BLKS/J, C57BL/6J, and SJL/J; 
GSE14270) using Affymetrix U133 plus 2.0 human expression arrays and Affymetrix GeneChip Mouse Genome 430 2.0 Arrays, respectively. Data (log2 
transformed) is shown for one representative probe in cases where there were multiple probes. A subset of these genes (i.e., PTGDS and HS3ST3B1, 
TBL1XR1 and ARID5B) was retested with quantitative PCR to validate the mouse microarray expression. In all cases, the results were consistent. 
a. Boxed loci indicate loci where the leading SNP was intergenic. 
b. Expression is summarized as absent (A) or present (P) based on expression greater than 5.0. 
c. Expression value is the average of the two human samples. 
d. Mouse homolog is the gene name used for the associated Affymetrix probe. 
e. Expression value is the average of the C57BL/6J samples. 
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Supplementary Figures: 
 
 
Supplementary Figure 1. Overall study design. 
We conducted a large meta-analysis of GWASs on CCT from over 20,000 individuals, including 
individuals of European and Asian descent, affected and unaffected with glaucoma. According to 
these attributes, the study samples with CCT phenotypes were divided into four sets (Set 1-4). We 
conducted meta-analyses within each set, and to enhance the power we conducted a further 
meta-analysis combining the first two sets (European and Asian samples unaffected with eye 
disease). We then tested the significant loci obtained from the trans-ethnic meta-analysis in the sets 
of glaucoma patients, in order to determine whether the CCT loci identified in the general population 
also influence the slightly reduced CCT values in the glaucoma patients. Finally, we tested the 
significant CCT loci for association with keratoconus and glaucoma risk in the disease cohorts, in 
order to evaluate the potential clinical relevance of the CCT loci.   
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Supplementary Figure 2. Q-Q plot of meta-analysis on Set 1 samples.  
 
The observed test statistics is plotted against the expected test statistics. The black line includes all 
SNP, the red line removes the known CCT-associated loci, and the blue line further removes the 
genome-wide significant loci we identified in Table 1. The genomic control parameter is shown as 
“lambda” in the plot.  
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Supplementary Figure 3 A-M. Regional plots of CCT associated loci in Table 1.  
 
The plots were generated using LocusZoom1 (URL:http://csg.sph.umich.edu/locuszoom/).  
 
 
 
  
34 
 
 
 
Supplementary Figure 4 A-C. Polygenic modeling with CCT meta-analysis results as 
discovery set. (A) CCT of 363 POAG patients in the ANZRAG study as target set. (B) US 
Keratoconus case-control set (222 cases and 3324 controls) as target; (C). Three 
glaucoma case-control sets (ANZRAG, GLAUGEN and NEIGHBOR) as target. The bars 
represent the -log10 p-value from the prediction model (-log10 p-value from meta-analysis 
of the three sets in (C)), and the lines represent the proportion of phenotypic variance 
explained.  
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Supplementary Notes: 
 
Study descriptions 
 
Lu et al. (2010)2: 
Datasets/Samples. This published study contained four main datasets from Australia and the 
United Kingdom. The AU twin cohort consisted of two sub-samples, 953 individuals from the 
Brisbane Adolescent Twin Study (BATS) and 761 individuals from the Twin Eye Study in Tasmania 
(TEST), making up a whole cohort of 1714 participants from 786 families. Twins from the UK were a 
sub-sample from the cohorts collected at St Thomas’ Hospital in London. 1759 people from 1119 
families were included in this study. The remaining two cohorts were genotyped on pooled samples 
from singletons with extreme CCT values. Blue Mountains Eye Study (BMES) used DNA pooling 
technique, namely BMES DNA pools and Adelaide study used blood pooling technique, namely 
Adelaide blood pools. All the datasets were mainly comprised of individuals with Northern European 
ancestries. Details of the cohorts are given in Lu et al (2010)2. 
 
Phenotypes. CCT was measured in these cohorts using ultrasound pachymetry and recorded for 
both eyes. Measurements were performed using a Tomey SP 2000 (Tomey Corp., Nagoya, Japan) 
in the Australian twin study and two pooling studies, and a DGH Technology (model 500; Scarsdale, 
NY) pachymeter in UK twin cohorts. Twin pairs were measured at the same time of day to avoid 
bias related to diurnal variation. The mean CCT value of both eyes was used throughout as the 
measurement. Mean, standard deviation (sd), range of CCT and age were provided in 
Supplementary Table 1, together with the proportion of females in the total dataset.  
 
Genotyping & Imputation. All of these datasets were genotyped using commercial genotyping 
platforms (Supplementary Table 1). Similar quality control (QC) were applied to the AU and UK twin 
study, including minor allele frequency (MAF)≥1%, p-value for Hardy-Weinberg equilibrium test≥10-6 
for AU twin study for 10-4 UK twin study, SNP call rate>95% or Illumina Beadstudio GenCall 
score≥0.7. QCs applied to the pooling studies included: more than 5 probes in each pool; with a 
MAF greater than 1%; without a significant variance difference between case and control pools (i.e., 
the log10 transformed p-values from an F test on the ratio of case control pool variances were 
smaller than 6).  
The imputation for the AU and UK twin samples were undertaken with reference to HapMap release 
22 CEU using MACH and IMPUTE version 2 respectively. Each of the imputed datasets contains up 
to 2.4 million SNPs. 
 
Analysis. Both AU and UK twin cohorts consist of either twin pairs or their close relatives (parents, 
siblings) in the family. We conducted the association test (--fastassoc) in MERLIN. The AU twin 
study was controlled for both age and gender effects, whilst the predominantly female UK samples 
were only controlled for age effects. The trait distribution of CCT was standardised. Two 
population-based cohorts were studied in the case-control pool design. The DNA or blood samples 
among the thick CCT group (upper 20% of the CCT distribution) were constructed as control pool, 
whereas samples among the thin CCT group (lower 20% of the CCT distribution) were constructed 
as case pool. We constructed the test statistics to take account of the pooling errors and assess the 
significance of allele frequency differences between the case/control pools. The pooled sample 
findings were validated by individual genotyping most of the pooled samples and additional 
samples.  
 
 
Vitart et al (2010)3:  
Datasets/Samples. The four populations (CROATIA-Vis, CROATIA-Korčula, CROATIA-Split, 
ORCADES) comprise healthy adult volunteers from the Croatian islands of Vis and Korčula, the 
Croatian urban city of Split and the northern isles of Orkney (Orkney Complex Disease Study, 
ORCADES, Scotland, UK). The studies received approval from relevant ethics committees in 
Scotland and Croatia and followed the tenets of the Declaration of Helsinki.  Briefly, the Vis study 
included unselected adult participants, aged 18–93 years (mean = 56), a subset of which (N=640) 
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underwent a complete eye examination in summer 2007 and provided their ophthalmologic history. 
The Korčula study included a total of 969 examinees, aged 18-98 (mean=56.3), and most (N=930) 
underwent a complete eye examination. ORCADES is a family-based, cross-sectional study in the 
Scottish archipelago of Orkney. Among 1,285 individuals with eye measurements, only 529 (aged 
22-88 (mean=55.1)) had been genotyped at the time of analysis. The Split study is a cross-sectional 
population study in the Croatian city of Split in which 499 individuals with whole-genome scans were 
available, aged 18-85 (mean=49.04), 372 of whom had undergone a complete eye examination. 
 
Phenotypes. Central corneal thickness (CCT) was recorded along with other ocular biometric 
measurements using a Nidek Echoscan US-1800 A-scan device in all three Croatian studies after 
application of sterile oxybuprocaine anaesthetic eye drops (Minims-Chauvin Pharmaceuticals Ltd). 
The Orkney measurements were performed using an IOPac ultrasound pachymeter (POD; 
Heidelberg engineering). Measures on eyes with a history of trauma, intra-ocular surgery or LASIK 
operations were removed. Right eye values were plotted against the left eye values. Pearson 
correlations for right and left eyes were highly statistically significant for CCT (2-tailed significance 
level of 0.01): 0.9 Korčula and Vis, 0.92 for Split, 0.97 for ORCADES. Given the high correlations 
between right and left eye measures, the analysis was done on the right eye measures, unless the 
left eye had more complete measurements (e.g. due to trauma or cataract surgery on the right eye). 
 
Genotyping & Imputation. Genotypes were generated using a dense Illumina SNP array, 
HumanHap 300v1 for Vis, a mix of HumanHap 300v2 and 370CNV-Quad for ORCADES, 
370CNV-Quad for Korčula, and 370CNV-Quadv3 for Split, following the manufacturer’s standard 
recommendations. Genotypes were determined using the Illumina BeadStudio software. Samples 
with a call rate below 97 % , potentially mixed samples with excess autosomal heterozygosity or 
gender discrepancy (based on the sex chromosomes genotypes), and ethnic outliers (based on 
principal components analysis of genotypic data), were excluded from the analysis using the quality 
control algorithm implemented in the R package GenABEL1. Imputation of allele dosage for over 2 
million SNPs on the 22 autosomal chromosomes with reference to HapMap CEU build 36 release 
22 was performed using the software MACH v1.0.15 after exclusion of SNP with MAF < 0.01, call 
rate < 98% and HWE deviation p< 10-6. 
 
Analysis. CCT measures were transformed into Z-scores for the association analysis (calculated 
by adjusting CCT measures for age and the three first principal components of ancestry and 
standardizing residuals using the ztransform command in GenABEL4). The ancestry principal 
components were obtained following multidimentional scaling of identity by state distances using 
the ibs and mds functions in GenABEL. 
Genome-wide association analysis was performed using a mixed linear model as implemented in 
the probABEL5 package  using the imputed SNP allele doses as an additive fixed effect and 
correcting for family relatedness using the polygenic6 and mmscore7 4 functions implemented in 
GenABEL and probABEL. 
URLs: http://mga.bionet.nsc.ru/~yurii/ABEL/ 
 
Rotterdam study: 
Datasets/Samples. The Rotterdam Study I (RS-I) is a prospective population-based cohort study of 
7983 residents aged 55 years and older living in Ommoord, a suburb of Rotterdam, the 
Netherlands8. Baseline examinations for the ophthalmic part took place between 1991 and 1993; 
follow-up examinations were performed from 1997 to 1999, from 2002 to 2006, and from 2009 (on 
going). The RS-II is another prospective population-based cohort study of 3011 residents aged 55 
years and older. The rationale and study design are similar to those of the RS-I8. The baseline 
examinations of RS-II took place between 2000 and 2002; follow-up examinations were performed 
from 2004 to 2005 and from 2009 (ongoing). The present study included only participants with valid 
central corneal thickness (CCT) and genotype data. 
All measurements in these studies were conducted after the Medical Ethics Committee of the 
Erasmus University had approved the study protocols and all participants had given a written 
informed consent in accordance with the Declaration of Helsinki. 
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Phenotypes. CCT measurements in the RS cohorts were done in a subset of participants. In RS-I, 
a total of 872 participants underwent CCT measurement, of which 200 were measured at baseline 
using ultrasound pachymetry (Allergan Humphrey 850, Carl Zeiss Meditec, Dublin, CA, USA)9 and 
672 at the third follow-up using non-contact biometer (Lenstar LS900, Haag-Streit, Köniz, 
Switzerland; see further). In RS-II, a total of 683 participants underwent CCT measurement using 
non-contact biometer. 
 
Genotyping & Imputation. In the RS-I and RS-II cohorts, DNA was genotyped by using the 
Illumina Infinium II HumanHap550chip v3.0 array according to the manufacturer’s protocols. 
Genotype data were imputed using HapMap CEU as a reference population, resulting in over 2.5 
million single nucleotide polymorphisms (SNPs). Extensive quality control analyses have been 
performed in each cohort. Participants with low-quality DNA were excluded. Details are described 
elsewhere10,11. 
 
Analysis. CCT from a random eye was used in the analysis if the values from both eyes were 
available. Within each study, linear regression models were used to examine the associations 
between SNPs and CCT adjusted for age and gender. The CCTs of a total of 102 participants of 
RS-I were assessed using both methods (ultrasound pachymetry in 1994 and non-contact biometer 
in 2009). The difference in time between both measurements was approximately 15 years. Although 
the CCT is constant over time and the correlation between both methods around 0.9, there was a 
systematic difference between both measurements (data not shown). In RS-I we therefore 
additionally adjusted for the method used for CCT measurement. All statistical analyses were 
performed using SPSS version 15.0.0 for Windows (SPSS inc., Chicago, IL, USA; 2006) and 
GRIMP12.  
 
 
Western Australia RAINE study: 
Datasets/Samples. Recruitment of the Western Australian Pregnancy (Raine) cohort has 
previously been described in detail13-15. In brief, between 1989 and 1991 2,900 pregnant women 
were recruited prior to 18-weeks gestation into a randomised controlled trial to evaluate the effects 
of repeated ultrasound in pregnancy. Children have been comprehensively phenotyped from birth to 
21 years of age (average ages of one, two, three, six, eight, ten, fourteen, seventeen and 
twenty-one) by trained members the Raine research team. Most of the children are of Caucasian 
ethnicity. Data collection included questionnaires completed by the child’s primary carer and by the 
adolescent from age 14, physical assessments by trained assessors at all follow up years, DNA 
collection from year 14 follow-up. The study was conducted with appropriate institutional ethics 
approval, and written informed consent was obtained from all mothers. 
 
Phenotypes. CCT was obtained from the Pupil Center Pachymetry readout obtained by anterior 
segment tomography of each dilated eye taken with an Oculus Pentacam (Optikgerate GmbH, 
Wetzlar, Germany). 
 
Genotyping & Imputation. Study individual genotype data was extracted from the genome-wide 
Illumina 660 Quad Array. Any pair of individuals who were related with a π > 0.1875 (in between 
second and third degree relatives – e.g. between half-sibs and cousins) was investigated and the 
individual with the higher proportion of missing data was excluded from the ‘clean’ dataset (68 
individuals excluded). Individuals who have low genotyping success (i.e. have lots of missing data) 
were excluded from the ‘clean’ dataset – a threshold of missingness > 3% was used for exclusion 
(16 individuals excluded). Additionally, if they had high levels of heterozygosity then they were also 
excluded (heterozygosity < 0.30 excluded 3 individual) as this may indicate sample contamination. 
In terms of genotyping success rates, we also excluded some SNPs if not satisfying: 
Hardy-Weinburg equilibrium p-value must be > 5.7x10-7 (919 markers); call rate must be >95% 
(97,718 markers); minor allele frequency must be >0.01 (1%) (119,246 markers – includes CNV’s). 
We have calculated the first five principal components which should be used in all GWAS analyses 
(at least the first two) to account for population stratification. These principal components were 
calculated using a subset of 42,888 SNPS that are not in LD with each other in the EIGENSTRAT 
package. 
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The MACH v1.0.16 (http://www.sph.umich.edu/csg/yli/mach/index.html) software was used for 
GWAS imputation on the 22 autosomes. Once the data was cleaned, a two step process was 
carried out using the CEU samples from HapMap phase2 build 36 release 22 as a reference panel: 
 
Analysis. Individual's mean CCT from each eye was used for analysis. With PLINK as an interface 
with R, a linear regression model was utilized to examine the association between SNPs and CCT 
adjusted for age, gender and the first two principal components, which account for population 
stratification in this cohort. 
 
 
DeCODE study:  
Datasets/Samples. The sample set from deCode consists of 708 individuals with CCT 
measurements, 409 clinically diagnosed glaucoma cases and 299 individuals without glaucoma 
from the Reykjavik Eye Study16. The glaucoma cases included 195 males and 214 females with 
mean age of 74.9 (SD 9.9), and the individuals from the Reykjavik Eye Study included 123 males 
and 176 females with a mean age of 69.0 (SD 9.0). 
Phenotypes. Two systems were used to ascertain central corneal thickness. The Reykjavik Eye 
Study used scheimpflug slit images of the cornea documented with the Nidek EAS 1000 automated 
eye analysis system (Nidek EAS 1000, Gamagori, Japan). This method has been found to be 
comparable to ultrasound pachometry17. The cases collected in clinical practices used Pachscan 
300p, sonomed Inc. USA ultrasound. The mean CCT values were 536 (SD 42) and 543 (SD 43) for 
the glaucoma cases and the non-glaucoma cases, respectively. 
Genotyping & Imputation. All samples were typed with the Illumina HumanHap300 or 
HumanHapCNV370 bead chips and only samples with more than 98% genotype yield were 
included in the analysis. After quality filtering, 290,350 SNPs were used to impute genotypes for 
additional 2,164,323 ungenotyped SNPs using the IMPUTE software18 and 114 phased haplotypes 
for the HapMap CEU samples (version 22) as a training set. 
 
Analysis. The analysis was done using the SNPTEST (version 2.1.1) software, assuming an 
additive model for the genetic effect by regressing the CCT values on the expected genotype counts 
adjusting for age and sex by including them as covariates in the analysis. A likelihood score test (the 
-method score option in SNPTEST) was used to take the genotype uncertainty into account. The 
glaucoma cases and the individuals without glaucoma were analyzed separately and the P-values 
were adjusted for relatedness of the individuals by dividing the corresponding χ2 statistic by 1.020 
and 1.017 for the analysis of glaucoma and non-glaucoma cases, respectively. 
 
 
Gutenberg Health Study:  
Datasets/Samples. The Gutenberg Health Study (GHS) is a population-based, prospective, 
observational cohort study in the Rhine-Main Region in midwestern Germany with a total of about 
15000 participants and follow-up after five years. The study sample is recruited from subjects aged 
between 35 and 74 years at the time of the exam. The sample was drawn randomly from local 
governmental registry offices and stratified by gender, residence (urban and rural) and decade of 
age. Exclusion criteria were insufficient knowledge of the German language to understand 
explanations and instructions, and physical or psychic inability to participate in the examinations in 
the study center. Individuals were invited for a 5-hour baseline-examination to the study center 
where clinical examinations and collection of blood samples were performed. An important feature 
of the study design is the interdisciplinary combination of an ophthalmological examination, general 
and especially cardiovascular examinations, psychosomatic evaluation, laboratory tests, and 
biobanking for proteomic and genetic analyses.  
 
Phenotypes. All participants underwent an ophthalmological investigation of 25 minutes’ duration 
taking place between 11:00 a.m. and 8:00 p.m. This examination was based on standard operating 
procedures and included a medical history of eye diseases, autorefraction and visual acuity testing 
(Humphrey® Automated Refractor/Keratometer (HARK) 599™, Carl Zeiss Meditec AG, Jena, 
Germany), visual field screening using frequency doubling technology (Humphrey® Matrix 
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Perimeter, Carl Zeiss Meditec AG, Jena, Germany), central corneal thickness and keratometry 
measurement (Scheimpflug imaging with the Pachycam™, Oculus, Wetzlar, Germany), slitlamp 
biomicroscopy with undilated pupils (Haag-Streit BM 900®, Bern, Switzerland) and non-mydriatic 
fundus photography (Visucam PRO NM,™, Carl Zeiss Meditec AG, Jena, Germany), all 
administered by an ophthalmologist. IOP was measured with a non-contact tonometer and 
automatic airpuff control (Nidek NT-2000™, Nidek Co., Japan). The study was approved by the 
Medical Ethics Committee of the University Medical Center Mainz and by the local and federal data 
safety commissioners. According to the tenets of the Declaration of Helsinki, written informed 
consent was obtained from all participants prior to entering the study. 
 
Genotyping & Imputation. Within GHS, DNA was extracted from buffy-coats from EDTA blood 
samples as described in Zeller et al19.Genotyping was performed on 3,463 individuals in 2008 (GHS 
I) and another 1,439 individuals in 2009 (GHS II) using the Affymetrix Genome-Wide Human SNP 
6.0 Array. DNA samples using the Affymetrix Genome-Wide Human SNP Nsp/Sty Assay 5.0 and 
hybridization were processed in accordance with the manufactures’ standard recommendations. 
Genotyped individuals were of European descent only. 
Genotypes were determined using the Birdseed v2 calling algorithm. Only samples with a contrast 
QC≥0.4 were included in the final genotype calling. Quality control on sample level comprised 
exclusion of samples with a call rate ≤97%, deviation from expected heterozygosity by more than 
three standard deviations, and relatedness based on identity by state distance measures. On the 
marker level we excluded polymorphisms with a call rate ≤98% in cases or controls, minor allele 
frequency ≤0.01 and deviation from Hardy-Weinberg equilibrium (P≤0.0001). Cluster plots were 
inspected for all markers with P<0.001 in the GWA analysis. After quality control, 2,996 individuals 
for GHS I and 1,179 individuals for GHS II remained for further analyses. Imputation was performed 
using Impute (v2.1.0) software (http://mathgen.stats.ox.ac.uk/impute/impute.html) according to the 
CEU HapMap 2 release 22 (build 36) reference dataset. Imputed genotypes were analyzed using the 
SNPTEST software taking genotype uncertainty into account 
(https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html). 
 
Analysis. Linear regression models with a 1 degree of freedom trend test were used to examine the 
associations between SNPs and CCT, adjusted for age and gender. We calculated regression 
coefficients using these linear regression models. The analysis was performed using PLINK 
software assuming an additive model. 
 
 
Singapore studies (Vithana et al (2011)20 and Cornes et al (2012)21): 
Datasets/Samples.  
The sample collections enrolled in Singapore have been previously described20,21. The enrollment 
of all sample collections adhered to the Declaration of Helsinki.  Ethics approval was obtained from 
the Singapore Eye Research Institute (SERI) Institutional Review Board (IRB). All participants were 
given a choice to provide written, informed consent in English, Malay, Mandarin, or using bilingual 
interviewers. Both versions of study information sheet and informed consent form were approved by 
the SERI IRB before the study commenced.  
SiMES is a population-based, cross-sectional study of 3280 Malay adults aged from 40 to 79 years. 
Details of the SiMES design, sampling plan, and methods have been reported elsewhere22. In brief, 
an age-stratified random sampling of all Malay adults, aged 40 to 80 years, residing in 15 residential 
districts in the south- western part of Singapore was drawn from the computer-generated random 
list of 16,069 Malay names provided by the Ministry of Home Affairs. A total of 1400 names from 
each decade of age (40-49, 50-59, 60-69, and 70-79 years), or 5600 names, were selected. Of 
these, 4168 individuals (74.4%) were determined to be eligible to participate. A person was 
considered ineligible if he or she had moved from the residential address, had not lived there in the 
past 6 months, was deceased, or was terminally ill. Of the 4168 eligible individuals, 3280 
participants (78.7%) took part in the study. The study was conducted from August 2004 through to 
June 2006.  
The SICC is designed to complement the SiMES in ethnic Indians and ethnic Chinese residents of 
Singapore.  This study was further divided into the Singapore Indian Eye Study (SINDI) and 
Singapore Chinese Eye Study (SCES).  Further information about the SICC has been published 
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elsewhere23. Similar to SiMES, the SINDI study is a population-based, cross-sectional 
epidemiological study, but of ethnic Indian adults aged between 40 and 80+ years residing in 
Singapore. As with SiMES, the Ministry of Home Affairs provided an initial computer-generated list 
of 12,000 ethnic Indian names derived from a simple random sampling of all ethnic Indian adults 
aged 40-80+ years of age residing in 15 residential districts in South-Western Singapore. From this 
list, a final sampling frame of 6,350 ethnic Indian residents was derived using an age-stratified 
random sampling strategy. SINDI was conducted from March 2007 to May 2007 and recruited 3,400 
(75% response rate) participants. 
SCES: In similar vein to SiMES and SINDI, the Singapore Chinese Eye Study (SCES) is a 
population-based, cross-sectional study of Chinese adults residing in the south- western part of 
Singapore.  The Ministry of Home Affairs provided an initial computer-generated list ethnic 
Chinese names of adults aged 40-80+ years of age. A final sampling frame of 6,350 ethnic Chinese 
residents was derived from this list using an age-stratified random sampling strategy similar to 
SiMES and SINDI. The ongoing SCES began in February, 2009 with an aim to recruit 3,300 (75% 
response rate) participants23. As of June 2011, we recruited and genotyped 1,952 participants, 
which was used in this analyses. 
 
Phenotypes.  
SiMES, SINDI, SCES: Five CCT measurements were obtained from each eye with an ultrasound 
pachymeter (Advent, Mentor O & O, Norwell, MA) and the median reading was taken24,25. As there 
was good correlation between the measurements in both eyes, only the readings from the right eye 
were used for analysis. 
 
Genotyping and Imputation. 
DNA was extracted from blood samples drawn from enrolled participants using standard laboratory 
techniques. Genome-wide genotyping of SINDI, SiMES and SCES was performed using the 
Illumina 610K Beadchip, as per manufacturer’s specifications.  
The imputation for the three Asian sample sets was undertaken using the imputation software 
IMPUTE. The HapMap Phase II JPT+CHB set was used as reference panel for the Chinese 
samples, and Phase III cosmopolitan panel (multi-ethnic) was used for the Indian and Malaysian 
samples. Stringent QC on imputation quality was applied (INFO>0.90). The numbers of imputed 
SNPs after QC were ~1.8 million for Chinese set and ~1 million for Indian or Malays.  
 
Analysis.  
Single cohort and meta-analysis of SINDI, SiMES, and SCES has been previously described21. For 
SINDI, 2516 samples passing quality checks had complete data for CCT measurements, age, and 
gender. For SiMES, 2514 samples passing quality checks had complete data for CCT 
measurements, age, and gender. For SCES, a final number of 1,883 individuals with complete data 
for CCT measurements, age and gender were available for analysis. We measured the association 
between SNP genotypes and CCT using linear regression modeling for genotype trend effects 
adjusted for age and gender. Further adjustment by incorporating the top principal components 
(PCs) of genetic stratification (PC1 to PC3 for SINDI, and PC1 plus PC2 for SiMES and SCES) was 
performed to minimize the effects of population stratification as previously described20,21.   
 
 
ANZRAG study (Burdon et al (2011)26): 
Datasets/Samples. Patients resident in Australia or New Zealand with advanced glaucoma were 
referred to the Australian and New Zealand Registry of Advanced Glaucoma by their treating 
ophthalmologist.  
 
Phenotypes. All participants met the Registry’s definition of advanced primary open angle 
glaucoma. Briefly, this was defined as best-corrected visual acuity worse than 6/60 due to POAG, or 
a reliable 24-2 Visual Field with a mean deviation of worse than -22db or at least 2 out of 4 central 
fixation squares affected with a Pattern Standard Deviation of < 0.5%. The field loss must be due to 
OAG, and the less severely affected eye was also required to have signs of glaucomatous disc 
damage. Secondary glaucoma and patients with mutations in MYOC were excluded. DNA was 
extracted from peripheral whole blood. 
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Genotyping & Imputation. 615 ANZRAG participants were genotyped on Illumina 
Human1M-Omni arrays. SNPs with a mean BeadStudio GenCall score <0.7 were excluded from the 
controls. All samples had successful genotypes for >95% of SNPs. SNPs with call rates either <0.95 
(minor allele frequency (MAF) > 0.05) or <0.99 (MAF > 0.01), Hardy-Weinberg equilibrium in 
controls P < 10.6 and/or MAF < 0.01 were excluded. Ancestry outliers were identified by principal 
component (PC) analysis using data from 11 populations of the HapMap 3 and 5 Northern 
European populations genotyped by the GenomeEUtwin consortium using the EIGENSOFT 
package and a subset of 160,000 independent SNPs. Twenty-five Individuals lying 2 standard 
deviations from the mean PC1 and PC2 scores were removed.. The imputation was undertaken 
with reference to 1000 Genome Pilot 1 (June 2010 version) using MACH. SNPs with small MAF 
(MAF<0.01) and low imputation quality (R2 <0.3) were discarded in the QC. 
 
Analysis. 363 participants had CCT data available and were used in this analysis. The association 
analysis was run in PLINK adjusting for age and sex.  
 
 
GLAUGEN study:  
Datasets/Samples. 976 cases and 1,140 controls collected from three study sites [Nurses Health 
study, Health Professionals Follow-up Study and the Genetic Etiologies of Primary-Open angle 
Glaucoma Study (GEP)] were genotyped for the GLAUGEN study. All cases and controls were 
residents of the continental United States and were of mainly European ancestry, which was 
confirmed by both self-identification and genetic markers. All individuals included in the GLAUGEN 
CCT analysis were POAG cases collected from the Massachusetts Eye and Ear Infirmary. 
 
Phenotypes. We observed a strong correlation between the right eye CCT and left eye CCT 
(R2=0.92) in the GLAUGEN study population. Therefore, we used the average CCT in the final 
analysis. We removed 10 outliers which are defined by large left-right differences (beyond 2.5 
standard deviation of the overall distribution of left-right differences). A lack of left/right eye 
correlation may be due to true difference between the eyes, measurement artefacts, or unknown 
corneal defects.  
 
Genotyping & Imputation. Genotyping was performed using the Illumina Human660W_Quad_v1 
array and 495,132 SNPs passed quality control filters.  Illumina’s BeadStudio and GenomeStudio 
and Autocall software along with genotype cluster definitions based on study samples were used to 
generate genotyping calls. SNPs with a GenTrain score <0.6, cluster separation score <0.4 and call 
rate <97% were considered technical failures at the genotyping center and were automatically 
deleted before release for further quality control. Subsequent data quality control measures 
consisted of identifying and removing samples with gender misidentification, unexpected duplicates 
and unexpected relatedness. Analysis of connectivity removed samples that appeared to be related 
to other samples and/or suggestive of contamination. Any SNP with missing call rate >2% or with 
Hardy Weinberg p-value < 10-4 in the control population was excluded. 
 
Analysis. We checked for population substructure using principal components analysis performed 
in Eigensoft. We identified 10 individuals as population outliers based on PCA results, four were 
self-reported Hispanic ethnicity. The ten PCA outliers were removed from the analysis and all 
remaining individuals were Caucasian. Linear regression was done using PLINK v1.07, included 
age and gender as covariates. 
 
 
NEIGHBOR study: 
Datasets/Samples. 2,170 cases and 2,347 controls collected from 12 sites throughout the United 
States were genotyped for the NEIGHBOR study. CCT data was available for individuals from all 
sites except for the University of California, San Diego and Stanford University. All cases and 
controls were residents of the continental United States and were of mainly European ancestry, 
which was confirmed by both self-identification and genetic markers. 
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Phenotypes. We observed a strong correlation between right eye CCT and left eye CCT (R2=0.83) 
in our sample, so we used the mean CCT as our primary analysis outcome. We removed 16 outliers 
which are defined by large left-right differences (beyond 2.5 standard deviation of the overall 
distribution of left-right differences) and 1 individual with an extremely small average CCT value 
(<374 microns). Additionally, we removed individuals with known corneal disease or known 
non-Caucasian ancestry. 
 
Genotyping & Imputation. Genotyping was performed using the Illumina Human660W_Quad_v1 
array and 523,528 SNPs passed quality control filters.   Allele cluster definitions for each SNP 
were determined using Illumina GenomeStudio Genotyping Module version 1.7.4, GenTrain version 
1.0 and the combined intensity data from 99.9% of the samples. The resulting cluster definitions 
were used on all samples. Genotypes were not called if the quality threshold (Gencall score) was 
below 0.15. Genotypes were released by CIDR for 557,029 SNPs (99.58% of attempted). 
Genotypes were not released for SNPs that had call rates less than 85%, more than 1 HapMap 
replicate error, cluster separation less than 0.2, more than a 3% (autosomal) or 2.2% (X 
chromosome) difference in call rate between genders, more than 0.4% (X chromosome) male 
heterozygosity, or more than a 8% (autosomal) difference in AB frequency. 
 
Analysis. We checked for population substructure using principal components analysis as 
implemented by EIGENSTRAT. After examining the top 10 PCs, we determined that the sample is a 
reasonably homogeneous population. Using a t-test, we compared the mean CCT between POAG 
cases and controls. We also found the instrument used to measure CCT (DGH Technology, Inc. 
ultrasound table unit versus portable handheld) had a significant effect on mean CCT 
(P-value<.001). Therefore, we included measurement device as covariates in the final model, along 
with age and gender. We performed linear regression using PLINK v1.07 for POAG cases and 
controls respectively. 
 
 
UK South Hampton study: 
Datasets/Samples. Four hundred (400) primary open angle patients from a cohort of patients being 
recruited in Hampshire (UK) were included in this study. Patients were recruited following the tenets 
of the declaration of Helsinki, informed consent was obtained and the research was approved by 
the Southampton & South West Hampshire Research Ethics Committee. Patients were all 
diagnosed as POAG cases and further defined as normal tension glaucoma (NTG) if the average 
IOP over both eyes ≤21 mmHg, and high tension glaucoma (HTG) if otherwise. All showed visual 
field loss in at least one eye. A full description of the cohort is given elsewhere27. Cases diagnosed 
as psuedoexfoliation glaucoma and those with a known myocilin mutation were excluded. 
 
Phenotypes. CCT information was available on 191 cases and 47 controls in this study. Cases 
were unrelated and of Caucasian ethnicity.  
 
Genotyping & Imputation. Primary open angle glaucoma patients (n=400) were genotyped on the 
Affymetrix SNP 6.0 array. Standard QC filtering followed, removing SNPs with MAF<5% and HWE 
p<0.001 (tested in controls but removed from cases and controls) and SNPs or samples with a high 
degree of missingness >10%. The HWE test (in controls) is generally used to control for genotyping 
error when cases and controls are genotyped together. However as the cases were genotyped 
separately extra QC steps were carried out. Firstly, the average confidence score for the genotypes 
(from the Affymetrix SNP calling software “Genotyping console”) were calculated for each SNP 
across individuals and SNPs with confidence scores which fell two standard deviations above the 
mean (worse confidence) were removed. We also removed SNPs with extreme deviations from 
HWE (p<1x10-10) in cases. 681,552 SNPs were available for analysis after QC. 
 
Analysis. A linear regression was carried out in PLINK for cases and controls separately using the 
average CCT over both eyes as the quantitative trait. Due to its relatively small sample size, the 
control set was not utilised in this meta-analysis. 
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Hong Kong cohort of normal tension glaucoma patients: 
Datasets/Samples. Patients with normal tension glaucoma (NTG) were recruited from the eye 
clinics of the Hong Kong Eye Hospital and the Prince of Wales Hospital, Hong Kong. Diagnosis of 
NTG was made after complete ophthalmic examinations and according to the following criteria: (1) 
no primary pathologies for glaucoma, e.g., trauma, uveitis, steroid-induced, exfoliation glaucoma, or 
neovascular glaucoma; (2) open anterior chamber angle, with Shaffer Grade 2 or above in dark 
room gonioscopy, without indentation; (3) evidence of characteristic glaucomatous optic disc 
changes including narrowing of the neuroretinal rim and/or thinning of the retinal nerve fiber layer; 
(4) fulfilling Anderson's criteria for minimal abnormality in glaucomatous visual field; and (5) highest 
recorded intraocular pressure below 21 mmHg. A total of 198 unrelated NTG patients were recruited, 
with all being Han Chinese. The mean (SD) age of study subjects was 64.1 (12.8) years. The 
female to male ratio was 1.02 (100/98). All patients have no other major eye diseases.  
The study protocol was approved by the Ethics Committee on Human Research of the Chinese 
University of Hong Kong. Informed consents were obtained from all study subjects. All procedures 
were conducted in accordance with the tenets of the Declaration of Helsinki. 
 
Phenotypes. Central corneal thickness (CCT) was measured for both eyes using a TOMEY SP 
3000 ultrasonic pachymeter (Tomey Corp., Nagoya, Japan). CCT in the both eyes followed normal 
distribution (P=0.80 and 0.29 in one-sample K-S test). The mean (SD) CCT was 536.0 (34.6) μm in 
the right eye and 537.2 (35.0) μm in the left eye. Since the CCT in the both eyes were highly 
correlated (Pearson correlation coefficient = 0.96, P=3.7x10-112) and were not significantly different 
between eyes (P=0.21, Student’s t-test), the mean CCT value of both eyes was used throughout as 
our analysis. Mean value of the CCT was 536.9 (34.5) μm.  
 
Genotyping & Imputation. The samples were genotyped on the Illumina CNV370Quad arrays at 
deCODE genetics, Iceland. SNPs on the X and Y chromosomes as well as the copy number variant 
(CNV) probes were removed from further analysis. A total of 1323 SNPs with call rates <95% were 
eliminated from the analysis. 37640 SNPs were also excluded as they had a minor allele frequency 
(MAF) < 1% and another 331 were excluded because of a significant deviation from 
Hardy-Weinberg Equilibrium (HWE) (p<10-4). After these steps, the number of individuals available 
with CCT measures and genotypes was 198 and the number of markers was 293,957. We 
examined potential genetic relatedness on the basis of pairwise identity by state for all the 
successfully genotyped samples by using PLINK 1.07 software. No relatedness was found. 
Potential population stratification was tested using the genomic control algorithm in PLINK. The 
genomic inflation factor (based on median chi-squared) was 1.0, suggesting a high degree of 
homogeneity of the study sample. 
 
Analysis. . A linear regression was carried out in PLINK v1.07 for the 198 NTG patients using the 
mean value of the CCT over both eyes as the quantitative trait. 
 
 
USA keratoconus study28:  
Samples. Clinically affected Caucasian keratoconus cases (N=240) were enrolled into the GWAS 
as a part of the longitudinal videokeratography and genetic study at the Cornea Genetic Eye 
Institute29. After removing samples with poor quality of genotyping, 222 samples were included in 
the analysis. Caucasian controls (N=3324) were obtained from the Cardiovascular Health Study 
(CHS), a population-based cohort study of risk factors for cardiovascular disease and stroke in 
adults 65 years of age or older, recruited at four field centers30,31. 5,201 predominantly Caucasian 
individuals were recruited in 1989-1990 from random samples of Medicare eligibility lists, followed 
by an additional 687 African-Americans recruited in 1992-1993 (total n= 5,888). CHS was approved 
by the Institutional Review Board at each recruitment site, and subjects provided informed consent 
for the use of their genetic information. African-American CHS participants were excluded from 
analysis due to insufficient number of ethnically-matched cases.  
 
Methods. IMPUTE version 2.1.018 was used to perform imputation of the genotyping data of SNPs 
rs1324183 and rs9938149 in keratoconus patients and CHS Caucasian controls using HapMap 
Phase I and II data (release #22 , NCBI Build 36) as the reference panel. Linkage disequilibrium 
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between lead SNPs and their proxies was calculated by a web-based computer tool SNAP using 
Caucasian panel32. 
 
 
Australian and Northern Ireland Keratoconus 
Datasets/Samples. Australian participants with keratoconus (n=517) were ascertained through the 
Department of Ophthalmology of Flinders Medical Centre, Adelaide, Australia; private optometry 
practices in Adelaide and Melbourne, Australia; the Royal Victorian Eye and Ear Hosptial, 
Melbourne, Australia; and by Australia-wide mail out to members of Keratoconus Australia, a 
community-based support group for patients. Patients from Northern Ireland (n=135) were recruited 
from the Ophthalmology Department of the Belfast Health and Social Care National Health System 
Trust. Clinical data were obtained from the participants’ eye care practitioner, and patients were 
included in the study only if they met the recruitment criteria. The Blue Mountains Eye Study was 
used as the control cohort. This population study of individuals over the age of 50 years living in the 
Blue Mountains area west of Sydney undertook detailed ophthalmic evaluations of all participants. 
2761 participants had genotyping information available. 
 
Phenotypes. The diagnosis of keratoconus was based on clinical examination and 
videokeratography pattern analysis. Clinical examination included slit lamp biomicroscopy, 
cycloplegic retinoscopy, and fundus evaluations. Slit lamp biomicroscopy was used to identify 
stromal corneal thinning, Vogt’s striae, or a Fleischer ring. A retinoscopic examination was 
performed with a fully dilated pupil to determine the presence or absence of retroillumination signs 
of keratoconus, such as the oil droplet sign and scissoring of the red reflex. Videokeratography 
evaluation was performed on each eye by topographic modeling. Patients were considered as 
having keratoconus if they had at least one clinical sign of the disease and by confirmatory 
videokeratography map with an asymmetric bowtie pattern with skewed radial axis above and 
below the horizontal meridian (AB/SRAX). A history of penetrating keratoplasty performed because 
of keratoconus was also sufficient for inclusion. 
 
Genotyping. Cases were genotyped in 2 plexes on a Sequenom Mass Array (Sequenom Inc) using 
iPlex gold chemistry (Sequenom Inc) at the Australian Genome Research Facility, Brisbane 
Australia. Four SNPs failed genotyping and were thus excluded from the analysis. Controls (Blue 
Mountains Eye Study) were genotyped on Illumina HumanHap 610 Arrays by the Wellcome Trust 
Case Control Consortium 2. Data relating to the genotyped SNPs were extracted for 2761 
genotyped samples and merged with the case data. 
 
Analysis. SNPs were assessed for allelic association in PLINK.  
 
 
 
 
Disease diagnostic criteria  
 
The diagnosis of keratoconus for Australia and Northern Ireland cases was based on clinical 
examination and videokeratography pattern analysis. Clinical examination included slit lamp 
biomicroscopy, cycloplegic retinoscopy, and fundus evaluations. Slit lamp biomicroscopy was used 
to identify stromal corneal thinning, Vogt’s striae, or a Fleischer ring. A retinoscopic examination was 
performed with a fully dilated pupil to determine the presence or absence of retroillumination signs 
of keratoconus, such as the oil droplet sign and scissoring of the red reflex. Videokeratography 
evaluation was performed on each eye by topographic modeling. Patients were considered as 
having keratoconus if they had at least one clinical sign of the disease and by confirmatory 
videokeratography map with an asymmetric bowtie pattern with skewed radial axis above and 
below the horizontal meridian (AB/SRAX). A history of penetrating keratoplasty performed because 
of keratoconus was also sufficient for inclusion. Similar diagnostic criteria were used in the US study, 
as previously described28.  
The POAG cases were defined in the GLAUGEN and NEIGHBOR studies as individuals for 
whom reliable visual field (VF) tests show characteristic VF defects consistent with glaucomatous 
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optic neuropathy. Individuals were classified as affected if the VF defects were reproduced on a 
subsequent test or if a single qualifying VF was accompanied by a cup-disc ratio (CDR) of 0.7 or 
more in at least one eye. The examination of the ocular anterior segment did not show signs of 
secondary causes for elevated IOP such as exfoliation syndrome or pigment dispersion syndrome 
and the filtration structures were deemed to be open based on clinical measures. Elevation of IOP 
was not a criterion for inclusion; however, 67% of cases did have a history of elevated IOP (≥22 mm 
Hg) measured in a clinical setting (typically between the hours of 8AM and 5PM) and were classified 
as high-pressure glaucoma (HPG). Cases with IOP <22 mm Hg measured in the clinic at the time of 
study enrollment (without treatment) were classified as normal-pressure glaucoma (NPG). Cases 
undergoing IOP-lowering therapy at the time of enrollment were included in the HPG group if they 
had a documented history of IOP >22 prior to treatment and cases undergoing IOP-lowering 
therapy at the time of enrollment were included in the NPG if they did not have recorded 
pressures >22 mmHg before treatment. As glaucoma patients are long-term patients with several 
clinic visits each year, for most of the glaucoma cases in this study the IOP measurements were 
made at least twice on multiple occasions. Controls had normal optic nerves (cup-disc ratios ≤0.6) 
and normal intraocular pressure (≤21 mm Hg)33.  
Enrolment in the advanced OAG category of ANZRAG was defined by severe visual loss 
resulting from OAG26. This includes best-corrected visual acuity worse than 6/60 due to OAG, or a 
reliable 24-2 Visual Field with a mean deviation of worse than -22db or at least 2 out of 4 central 
fixation squares affected with a Pattern Standard Deviation of < 0.5%. The field loss must be due to 
OAG, and the less severely affected eye was also required to have signs of glaucomatous disc 
damage. Clinical exclusion criteria for this study included: i) pseudoexfoliation or pigmentary 
glaucoma, ii) angle closure or mixed mechanism glaucoma, iii) secondary glaucoma due to aphakia, 
rubella, rubeosis or inflammation, iv) infantile glaucoma, v) glaucoma in the presence of a known 
associated syndrome, vi) mutation in the MYOC gene (by direct sequencing of exon 3). Identical 
criteria were applied to GIST participants to select equivalent advanced glaucoma cases. The 
controls were not screened for glaucoma and hence will include some present (or future) glaucoma 
cases. Although this slightly reduces power to test for association relative to screened controls, 
given the low prevalence of advanced glaucoma (~ 3/1000), the reduction in power is likely to be 
small. 
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